0001213900-19-015337.txt : 20190812 0001213900-19-015337.hdr.sgml : 20190812 20190812161123 ACCESSION NUMBER: 0001213900-19-015337 CONFORMED SUBMISSION TYPE: 10-Q PUBLIC DOCUMENT COUNT: 41 CONFORMED PERIOD OF REPORT: 20190630 FILED AS OF DATE: 20190812 DATE AS OF CHANGE: 20190812 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Health Sciences Acquisitions Corp CENTRAL INDEX KEY: 0001764013 STANDARD INDUSTRIAL CLASSIFICATION: BLANK CHECKS [6770] IRS NUMBER: 832771572 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 10-Q SEC ACT: 1934 Act SEC FILE NUMBER: 001-38906 FILM NUMBER: 191016635 BUSINESS ADDRESS: STREET 1: 412 W. 15TH STREET STREET 2: FLOOR 9 CITY: NEW YORK STATE: NY ZIP: 10011 BUSINESS PHONE: 646-343-9298 MAIL ADDRESS: STREET 1: 412 W. 15TH STREET STREET 2: FLOOR 9 CITY: NEW YORK STATE: NY ZIP: 10011 10-Q 1 f10q0619_healthsciences.htm QUARTERLY REPORT

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 10-Q

(Mark One)

☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the quarterly period ended June 30, 2019

☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the transition period from to

Commission File No. 001-38906

Health Sciences Acquisitions Corporation

(Exact name of registrant as specified in its charter)

Delaware

83-2771572

(State or other jurisdiction of

incorporation or organization)

(I.R.S. Employer

Identification No.)

412 West 15^th Street, Floor 9

New York, NY 10011

(Address of Principal Executive Offices, including zip code)

(646) 343-9280

(Registrant’s telephone number, including area code)

N/A

(Former name, former address and former fiscal year, if changed since last report)

Securities registered pursuant to Section 12(b) of the Act:

Title of each class	Trading Symbol(s)	Name of each exchange on which registered
Units, each consisting of one share of Common Stock, $0.0001 par value, and one Warrant entitling the holder to receive one half share of Common Stock	HSACU	The NASDAQ Stock Market LLC
Shares of Common Stock, $0.0001 par value, included as part of the Units	HSAC	The NASDAQ Stock Market LLC
Warrants included as part of the Units	HSACW	The NASDAQ Stock Market LLC

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes ☒ No ☐

Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). Yes ☒ No ☐

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

☐	Large accelerated filer	☐	Accelerated filer
☒	Non-accelerated filer	☒	Smaller reporting company
		☒	Emerging growth company

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act): Yes ☒ No ☐

As of August 12, 2019, there were 14,375,000 shares of common stock, $0.0001 par value, issued and outstanding.

HEALTH SCIENCES ACQUISITIONS CORPORTATION

Quarterly Report on Form 10-Q

TABLE OF CONTENTS

		Page

PART 1 – FINANCIAL INFORMATION

Item 1.	Financial Statements

	Condensed Balance Sheets as of June 30, 2019 (unaudited) and December 31, 2018	1

	Condensed Statements of Operations for the Three and Six Months Ended June 30, 2019 (unaudited)	2

	Condensed Statements of Changes in Stockholders’ Equity for the Three and Six Months Ended June 30, 2019 (unaudited)	3

	Condensed Statement of Cash Flows for the Six Months Ended June 30, 2019 (unaudited)	4

	Notes to Condensed Financial Statements (unaudited)	5

Item 2.	Management’s Discussion and Analysis of Financial Condition and Results of Operations	13

Item 3.	Quantitative and Qualitative Disclosures about Market Risk	15

Item 4.	Control and Procedures	15

PART II – OTHER INFORMATION

Item 1.	Legal Proceedings	16

Item 1A.	Risk Factors	16

Item 2.	Unregistered Sales of Equity Securities and Use of Proceeds	16

Item 3.	Defaults Upon Senior Securities	16

Item 4.	Mine Safety Disclosures	16

Item 5.	Other Information	16

Item 6.	Exhibits	16

SIGNATURES		17

PART 1 - FINANCIAL INFORMATION

Item 1. Interim Financial Statements.

HEALTH SCIENCES ACQUISITIONS CORPORATION

CONDENSED BALANCE SHEETS

	June 30,		December 31,
	2019		2018
	(Unaudited)
ASSETS
Current assets
Cash	$	1,911,852	$	325,000
Prepaid expenses		162,093		—
Total Current Assets		2,073,945

Deferred offering costs		—		80,000
Cash and Marketable securities held in Trust Account		115,341,558		—
Total Assets	$	117,415,503	$	405,000

LIABILITIES AND STOCKHOLDERS’ EQUITY
Current liabilities
Accrued expenses	$	24,600	$	448
Accrued offering costs		—		80,000
Income taxes payable		66,467		—
Promissory note – related party		—		300,000
Total Current Liabilities		91,067		380,448

Deferred underwriting fee payable		4,025,000		—
Total Liabilities		4,116,067		380,448

Commitments and contingencies (Note 5)

Common stock subject to possible redemption, 10,829,943 shares at redemption value		108,299,430		—

Stockholders’ Equity
Common stock, $0.0001 par value; 30,000,000 shares authorized; 3,545,057 and 2,875,000 shares issued and outstanding (excluding 10,829,943 and no shares subject to possible redemption) as of June 30, 2019 and December 31, 2018, respectively ⁽¹⁾		355		288
Additional paid-in capital		4,817,800		24,712
Retained earnings/(Accumulated deficit)		181,851		(448	)
Total Stockholders’ Equity		5,000,006		24,552
Total Liabilities and Stockholders’ Equity	$	117,415,503	$	405,000

(1)

Included up to 375,000 shares subject to forfeiture if the over-allotment option was not exercised in full or in part by the underwriters (see Note 4).

The accompanying notes are an integral part of the unaudited condensed financial statements.

HEALTH SCIENCES ACQUISITIONS CORPORATION

CONDENSED STATEMENTS OF OPERATIONS

(Unaudited)

	Three Months Ended June 30,			Six Months Ended June 30,
	2019			2019

Operating costs	$	67,742		$	67,742
Franchise taxes		24,600			25,050
Loss from operations		(92,342	)		(92,792	)

Other income:
Interest income		341,558			341,558

Income before provision for income taxes		249,216			248,766
Provision for income taxes		(66,467	)		(66,467	)
Net income	$	182,749		$	182,299

Weighted average shares outstanding of redeemable common stock		11,500,000			11,500,000
Basic and diluted net income per share, redeemable common stock	$	0.02		$	0.02

Weighted average shares outstanding of non-redeemable common stock		2,875,000			2,875,000
Basic and diluted net loss per share, non-redeemable common stock	$	(0.02	)	$	(0.02	)

The accompanying notes are an integral part of the unaudited condensed financial statements.

HEALTH SCIENCES ACQUISITIONS CORPORATION

CONDENSED STATEMENTS OF CHANGES IN STOCKHOLDERS’ EQUITY

THREE AND SIX MONTHS ENDED JUNE 30, 2019

(Unaudited)

	Common Stock ⁽¹⁾						Additional Paid			Retained Earnings/ (Accumulated			Total Stockholders’
	Shares			Amount			in Capital			Deficit)			Equity
Balance – January 1, 2019		2,875,000		$	288		$	24,712		$	(448	)	$	24,552

Net loss		—			—			—			(450	)		(450	)

Balance – March 31, 2019 (unaudited)		2,875,000		$	288		$	24,712		$	(898	)	$	24,102

Sale of 11,500,000 Units, net of underwriting discounts and offering costs		11,500,000			1,150			108,091,435			—			108,092,585

Sale of 10,000,000 Private Warrants		—			—			5,000,000			—			5,000,000

Common stock subject to possible redemption		(10,829,943	)		(1,083	)		(108,298,347	)		—			(108,299,430	)

Net income		—			—			—			182,749			182,749

Balance – June 30, 2019 (unaudited)		3,545,057		$	355		$	4,817,800		$	181,851		$	5,000,006

(1)

Included up to 375,000 shares subject to forfeiture if the over-allotment option was not exercised in full or in part by the underwriters (see Note 4).

The accompanying notes are an integral part of the unaudited condensed financial statements.

HEALTH SCIENCES ACQUISITIONS CORPORATION

CONDENSED STATEMENT OF CASH FLOWS

SIX MONTHS ENDED JUNE 30, 2019

(Unaudited)

Cash Flows from Operating Activities:
Net income	$	182,299
Adjustments to reconcile net income to net cash used in operating activities:
Interest earned on cash and marketable securities held in Trust Account		(341,588	)
Changes in operating assets and liabilities:
Prepaid expenses		(162,093	)
Accrued expenses		24,152
Income taxes payable		66,467
Net cash used in operating activities		(230,733	)

Cash Flows from Investing Activities:
Investment of cash into Trust Account		(115,000,000	)
Net cash used in investing activities		(115,000,000	)

Cash Flows from Financing Activities:
Proceeds from sale of Units, net of underwriting discounts paid		112,700,000
Proceeds from sale of Private Warrants		5,000,000
Advances from related party		50,000
Repayment of advances from related party		(50,000	)
Repayment of promissory note – related party		(300,000	)
Payment of offering costs		(582,415	)
Net cash provided by financing activities		116,817,585

Net Change in Cash		1,586,852
Cash – Beginning of period		325,000
Cash – End of period	$	1,911,852

Non-Cash investing and financing activities:
Initial classification of common stock subject to possible redemption	$	108,116,280
Change in value of common stock subject to possible redemption	$	183,150
Deferred underwriting fee payable	$	4,025,000

The accompanying notes are an integral part of the unaudited condensed financial statements.

HEALTH SCIENCES ACQUISITIONS CORPORATION

NOTES TO CONDENSED FINANCIAL STATEMENTS

JUNE 30, 2019

(Unaudited)

NOTE 1. DESCRIPTION OF ORGANIZATION AND BUSINESS OPERATIONS

Health Sciences Acquisitions Corporation (the “Company”) was incorporated in Delaware on December 6, 2018. The Company was formed for the purpose of effecting a merger, share exchange, asset acquisition, stock purchase, recapitalization, reorganization or similar business combination with one or more businesses (the “Business Combination”).

Although the Company is not limited to a particular or geographic region for purposes of consummating a Business Combination, the Company intends to focus on businesses in the healthcare and healthcare-related industries in North America or Europe. The Company is an emerging growth company and, as such, the Company is subject to all of the risks associated with emerging growth companies.

As of June 30, 2019, the Company had not commenced any operations, other than searching for a target business. All activity for the period from December 6, 2018 (inception) through June 30, 2019 relates to the Company’s formation, the initial public offering (“Initial Public Offering”), which is described below, and identifying a target company for a Business Combination. The Company will not generate any operating revenues until after the completion of its initial Business Combination, at the earliest. The Company generates non-operating income in the form of interest income from the proceeds derived from the Initial Public Offering.

The registration statement for the Company’s Initial Public Offering was declared effective on May 9, 2019. On May 14, 2019, the Company consummated the Initial Public Offering of 11,500,000 units (the “Units” and, with respect to the shares common stock included in the Units sold, the “Public Shares”), which includes the full exercise by the underwriters of the over-allotment option, at $10.00 per Unit, generating gross proceeds of $115,000,000, which is described in Note 3.

Simultaneously with the closing of the Initial Public Offering, the Company consummated the sale of 10,000,000 warrants (the “Private Warrants”) at a price of $0.50 per Private Warrant in a private placement to Health Sciences Holdings, LLC, a Delaware limited liability company (the “Sponsor”), generating gross proceeds of $5,000,000, which is described in Note 4.

Transaction costs amounted to $6,907,415, consisting of $2,300,000 of underwriting fees, $4,025,000 of deferred underwriting fees and $582,415 of other offering costs. At June 30, 2019, $1,911,852 of cash was held outside of the Trust Account (as defined below) and is available for working capital purposes.

Following the closing of the Initial Public Offering on May 14, 2019, an amount of $115,000,000 ($10.00 per Unit) from the net proceeds of the sale of the Units in the Initial Public Offering and the sale of the Private Warrants was placed in a trust account (“Trust Account”) which will be invested in U.S. government securities, within the meaning set forth in Section 2(a)(16) of the Investment Company Act of 1940, as amended (the “Investment Company Act”), with a maturity of 180 days or less or in any open-ended investment company that holds itself out as a money market fund meeting the conditions of Rule 2a-7 of the Investment Company Act, as determined by the Company, until the earlier of: (i) the completion of a Business Combination or (ii) the distribution of the Trust Account, as described below.

The Company’s management has broad discretion with respect to the specific application of the net proceeds of the Initial Public Offering and the sale of the Private Warrants, although substantially all of the net proceeds are intended to be applied generally toward consummating a Business Combination. The Company’s initial Business Combination must be with one or more target businesses that together have a fair market value of at least 80% of the assets held in the Trust Account (excluding the deferred underwriting fees and taxes payable on the income earned on the Trust Account) at the time of the agreement to enter into a Business Combination. The Company will only complete a Business Combination if the post-transaction Company owns or acquires 50% or more of the outstanding voting securities of the target or otherwise acquires a controlling interest in the target sufficient for it not to be required to register as an investment company under the Investment Company Act 1940, as amended (the “Investment Company Act”). There is no assurance that the Company will be able to complete a Business Combination successfully.

The Company will provide its holders of the outstanding Public Shares (the “public stockholders”) with the opportunity to convert all or a portion of their Public Shares upon the completion of a Business Combination either (i) in connection with a stockholder meeting called to approve the Business Combination or (ii) by means of a tender offer. The decision as to whether the Company will seek stockholder approval of a Business Combination or conduct a tender offer will be made by the Company, solely in its discretion. The public stockholders will be entitled to convert their Public Shares for a pro rata portion of the amount then in the Trust Account (initially $10.00 per Public Share, plus any pro rata interest earned on the funds held in the Trust Account and not previously released to the Company to pay its income and franchise tax obligations). There will be no redemption rights upon the completion of a Business Combination with respect to the Company’s warrants.

HEALTH SCIENCES ACQUISITIONS CORPORATION

NOTES TO CONDENSED FINANCIAL STATEMENTS

JUNE 30, 2019

(Unaudited)

The Company will proceed with a Business Combination if the Company has net tangible assets of at least $5,000,001 upon such consummation of a Business Combination and, if the Company seeks stockholder approval, a majority of the shares voted are voted in favor of the Business Combination. If a stockholder vote is not required by law and the Company does not decide to hold a stockholder vote for business or other legal reasons, the Company will, pursuant to its Amended and Restated Certificate of Incorporation, conduct the redemptions pursuant to the tender offer rules of the U.S. Securities and Exchange Commission (“SEC”) and file tender offer documents with the SEC prior to completing a Business Combination. If, however, stockholder approval of the transactions is required by law, or the Company decides to obtain stockholder approval for business or legal reasons, the Company will offer to redeem shares in conjunction with a proxy solicitation pursuant to the proxy rules and not pursuant to the tender offer rules. If the Company seeks stockholder approval in connection with a Business Combination, the Company’s Sponsor, officers and directors (the “initial stockholders”) have agreed (i) to vote their Founder Shares (as defined in Note 4) and any Public Shares acquired in or after the Initial Public Offering in favor of a Business Combination, (ii) not to convert any shares owned by them in connection therewith and (iii) not to sell any of their shares to the Company in a tender offer. Additionally, each public stockholder may elect to convert their Public Shares irrespective of whether they vote for or against the proposed transaction.

Notwithstanding the foregoing, if the Company seeks stockholder approval of a Business Combination and it does not conduct conversions pursuant to the tender offer rules, the Amended and Restated Certificate of Incorporation provides that a public stockholder, together with any affiliate of such stockholder or any other person with whom such stockholder is acting in concert or as a “group” (as defined under Section 13 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”)), will be restricted from converting its shares with respect to more than an aggregate of 20% or more of the Public Shares, without the prior consent of the Company.

The initial stockholders have agreed (a) to waive their redemption rights with respect to their Founder Shares and Public Shares held by them in connection with the completion of a Business Combination and (b) not to propose, or vote in favor of, an amendment to the Amended and Restated Certificate of Incorporation that would affect the substance or timing of the Company’s obligation to redeem 100% of its Public Shares if the Company does not complete a Business Combination, unless the Company provides the public stockholders with the opportunity to redeem their Public Shares in conjunction with any such amendment.

The Company will have until May 14, 2021 to complete a Business Combination (the “Combination Period”). If the Company is unable to complete a Business Combination within the Combination Period, the Company will (i) cease all operations except for the purpose of winding up, (ii) as promptly as reasonably possible but not more than ten business days thereafter, redeem 100% of the outstanding Public Shares for a pro rata portion of the funds held in the Trust Account, which redemption will completely extinguish public stockholders’ rights as stockholders (including the right to receive further liquidating distributions, if any), subject to applicable law, and (iii) as promptly as reasonably possible following such redemption, subject to the approval of the Company’s remaining stockholders and the Company’s board of directors, dissolve and liquidate, subject in each case to the Company’s obligations under Delaware law to provide for claims of creditors and the requirements of other applicable law. There will be no redemption rights or liquidating distributions with respect to the Company’s warrants, which will expire worthless if the Company fails to complete a Business Combination within the Combination Period.

The initial stockholders have agreed to waive their liquidation rights with respect to the Founder Shares and Private Shares if the Company fails to complete a Business Combination within the Combination Period. However, if the Sponsor, officers and directors acquire Public Shares in or after the Initial Public Offering, such Public Shares will be entitled to liquidating distributions from the Trust Account if the Company fails to complete a Business Combination within the Combination Period. The underwriters have agreed to waive their rights to their deferred underwriting commissions (see Note 5) held in the Trust Account in the event the Company does not complete a Business Combination within the Combination Period and, in such event, such amounts will be included with the funds held in the Trust Account that will be available to fund the redemption of the Public Shares. In the event of such distribution, it is possible that the per share value of the assets remaining available for distribution will be less than the Initial Public Offering price per Unit ($10.00).

In order to protect the amounts held in the Trust Account, the initial stockholders have agreed to be liable to the Company if and to the extent any claims by a vendor for services rendered or products sold to the Company, or a prospective target business with which the Company has discussed entering into a transaction agreement, reduce the amounts in the Trust Account to below $10.00 per Public Share, except as to any claims by a third party who executed a valid and enforceable agreement with us waiving any right, title, interest or claim of any kind they may have in or to any monies held in the trust account and except as to any claims under our indemnity of the underwriters from our Initial Public Offering against certain liabilities, including liabilities under the Securities Act of 1933, as amended (the “Securities Act”). Moreover, in the event that an executed waiver is deemed to be unenforceable against a third party, the initial stockholders will not be responsible to the extent of any liability for such third-party claims. The Company will seek to reduce the possibility that the initial stockholders will have to indemnify the Trust Account due to claims of creditors by endeavoring to have all vendors, service providers (except the Company’s independent registered accounting firm), prospective target businesses or other entities with which the Company does business, execute agreements with the Company waiving any right, title, interest or claim of any kind in or to monies held in the Trust Account.

HEALTH SCIENCES ACQUISITIONS CORPORATION

NOTES TO CONDENSED FINANCIAL STATEMENTS

JUNE 30, 2019

(Unaudited)

NOTE 2. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

Basis of presentation

The accompanying unaudited condensed financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America (“GAAP”) for interim financial information and in accordance with the instructions to Form 10-Q and Article 8 of Regulation S-X of the SEC. Certain information or footnote disclosures normally included in financial statements prepared in accordance with GAAP have been condensed or omitted, pursuant to the rules and regulations of the SEC for interim financial reporting. Accordingly, they do not include all the information and footnotes necessary for a complete presentation of financial position, results of operations, or cash flows. In the opinion of management, the accompanying unaudited condensed financial statements include all adjustments, consisting of a normal recurring nature, which are necessary for a fair presentation of the financial position, operating results and cash flows for the periods presented.

The accompanying unaudited condensed financial statements should be read in conjunction with the Company’s prospectus for its Initial Public Offering as filed with the SEC on May 10, 2019, as well as the Company’s Current Report on Form 8-K, as filed with the SEC on May 15, 2019. The interim results for the three and six months ended June 30, 2019 are not necessarily indicative of the results to be expected for the year ended December 31, 2019 or for any future periods.

Emerging growth company

The Company is an “emerging growth company,” as defined in Section 2(a) of the Securities Act, as modified by the Jumpstart Our Business Startups Act of 2012 (the “JOBS Act”), and it may take advantage of certain exemptions from various reporting requirements that are applicable to other public companies that are not emerging growth companies including, but not limited to, not being required to comply with the independent registered public accounting firm attestation requirements of Section 404 of the Sarbanes-Oxley Act, reduced disclosure obligations regarding executive compensation in its periodic reports and proxy statements, and exemptions from the requirements of holding a nonbinding advisory vote on executive compensation and stockholder approval of any golden parachute payments not previously approved.

Further, Section 102(b)(1) of the JOBS Act exempts emerging growth companies from being required to comply with new or revised financial accounting standards until private companies (that is, those that have not had a Securities Act registration statement declared effective or do not have a class of securities registered under the Exchange Act) are required to comply with the new or revised financial accounting standards. The JOBS Act provides that a company can elect to opt out of the extended transition period and comply with the requirements that apply to non-emerging growth companies but any such election to opt out is irrevocable. The Company has elected not to opt out of such extended transition period, which means that when a standard is issued or revised and it has different application dates for public or private companies, the Company, as an emerging growth company, can adopt the new or revised standard at the time private companies adopt the new or revised standard. This may make comparison of the Company’s financial statements with another public company which is neither an emerging growth company nor an emerging growth company which has opted out of using the extended transition period difficult or impossible because of the potential differences in accounting standards used.

Use of estimates

The preparation of condensed financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the condensed financial statements and the reported amounts of revenues and expenses during the reporting period.

Making estimates requires management to exercise significant judgment. It is at least reasonably possible that the estimate of the effect of a condition, situation or set of circumstances that existed at the date of the financial statement, which management considered in formulating its estimate, could change in the near term due to one or more future confirming events. Accordingly, the actual results could differ significantly from those estimates.

HEALTH SCIENCES ACQUISITIONS CORPORATION

NOTES TO CONDENSED FINANCIAL STATEMENTS

JUNE 30, 2019

(Unaudited)

Common stock subject to possible redemption

The Company accounts for its common stock subject to possible redemption in accordance with the guidance in Accounting Standards Codification (“ASC”) Topic 480 “Distinguishing Liabilities from Equity.” Common stock subject to mandatory redemption is classified as a liability instrument and is measured at fair value. Conditionally redeemable common stock (including common stock that features redemption rights that is either within the control of the holder or subject to redemption upon the occurrence of uncertain events not solely within the Company’s control) is classified as temporary equity. At all other times, common stock is classified as stockholders’ equity. The Company’s common stock features certain redemption rights that are considered to be outside of the Company’s control and subject to occurrence of uncertain future events. Accordingly, at June 30, 2019, common stock subject to possible redemption is presented as temporary equity, outside of the stockholders’ equity section of the Company’s condensed balance sheet.

Offering costs

Offering costs consist of legal, accounting, underwriting fees and other costs incurred through the balance sheet date that were directly related to the Initial Public Offering. Offering costs amounting to $6,907,415 were charged to stockholders’ equity upon the completion of the Initial Public Offering.

Income taxes

The Company follows the asset and liability method of accounting for income taxes under ASC 740, “Income Taxes.” Deferred tax assets and liabilities are recognized for the estimated future tax consequences attributable to differences between the financial statements carrying amounts of existing assets and liabilities and their respective tax bases. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in income in the period that included the enactment date. Valuation allowances are established, when necessary, to reduce deferred tax assets to the amount expected to be realized. As of June 30, 2019 and December 31, 2018, the Company had a deferred tax asset of approximately $14,000 and $0, respectively, which had a full valuation allowance recorded against it of approximately $4,000 and $30, respectively. Deferred tax assets were not deemed to be material as of June 30, 2019 and December 31, 2018.

The Company’s currently taxable income primarily consists of interest income on the Trust Account. The Company’s general and administrative costs are generally considered start-up costs and are not currently deductible. During the three and six months ended June 30, 2019, the Company recorded income tax expense of approximately $66,000 respectively, primarily related to interest income earned on the Trust Account. The Company’s effective tax rate for the three and six months ended June 30, 2019 was approximately 26.7% respectively which differs from the expected income tax rate due to the start-up costs (discussed above) which are not currently deductible.

ASC 740 prescribes a recognition threshold and a measurement attribute for the financial statement recognition and measurement of tax positions taken or expected to be taken in a tax return. For those benefits to be recognized, a tax position must be more likely than not to be sustained upon examination by taxing authorities. The Company recognizes accrued interest and penalties related to unrecognized tax benefits as income tax expense. There were no unrecognized tax benefits and no amounts accrued for interest and penalties as of June 30, 2019 and December 31, 2018. The Company is currently not aware of any issues under review that could result in significant payments, accruals or material deviation from its position. The Company is subject to income tax examinations by major taxing authorities since inception.

Net loss per share

Net income (loss) per common share is computed by dividing net income (loss) by the weighted average number of common shares outstanding for the period. The Company has not considered the effect of warrants sold in the Initial Public Offering and private placement to purchase an aggregate of 10,750,000 shares of common stock in the calculation of diluted income (loss) per share, since the exercise of the warrants are contingent upon the occurrence of future events and the inclusion of such warrants would be anti-dilutive under the treasury stock method.

The Company’s statements of operations includes a presentation of income (loss) per share for common shares subject to redemption in a manner similar to the two-class method of income per share. Net income per common share, basic and diluted for redeemable common stock is calculated by dividing the interest income earned on the Trust Account, net of applicable franchise and income taxes of approximately $92,000, by the weighted average number of shares of redeemable common stock outstanding. Net loss per common share, basic and diluted for non-redeemable common stock is calculated by dividing the net income (loss), less income attributable to redeemable common stock, by the weighted average number of non-redeemable common stock outstanding for the period. Non-redeemable common stock includes the Founder Shares as these shares do not have any redemption features and do not participate in the income earned on the Trust Account.

Concentration of credit risk

Financial instruments that potentially subject the Company to concentration of credit risk consist of a cash account in a financial institution, which, at times, may exceed the Federal Depository Insurance Coverage of $250,000. At June 30, 2019 and December 31, 2018, the Company had not experienced losses on this account and management believes the Company is not exposed to significant risks on such account.

HEALTH SCIENCES ACQUISITIONS CORPORATION

NOTES TO CONDENSED FINANCIAL STATEMENTS

JUNE 30, 2019

(Unaudited)

Financial instruments

The fair value of the Company’s assets and liabilities, which qualify as financial instruments under ASC Topic 820, “Fair Value Measurements and Disclosures,” approximates the carrying amounts represented in the accompanying condensed balance sheets, primarily due to their short-term nature.

Recently issued accounting standards

Management does not believe that any recently issued, but not yet effective, accounting pronouncements, if currently adopted, would have a material effect on the Company’s condensed financial statements.

NOTE 3. INITIAL PUBLIC OFFERING

Pursuant to the Initial Public Offering, the Company sold 11,500,000 Units at a purchase price of $10.00 per Unit, which includes the full exercise by the underwriters of their option to purchase an additional 1,500,000 Units at $10.00 per Unit. Each Unit consists of one share of common stock and one redeemable warrant (“Public Warrant”). Each Public Warrant entitles the holder to purchase one-half of one share of common stock at a price of $11.50 per whole share, subject to adjustment (see Note 6).

NOTE 4. RELATED PARTY TRANSACTIONS

Founder Shares

In December 2018, the Sponsor purchased 2,875,000 shares (the “Founder Shares”) of the Company’s common stock for an aggregate price of $25,000. The Founder Shares included an aggregate of up to 375,000 shares subject to forfeiture to the extent that the underwriters’ over-allotment option was not exercised in full or in part, so that the initial stockholders would own, on an as-converted basis, 20% of the Company’s issued and outstanding shares after the Initial Public Offering (assuming the initial stockholders did not purchase any Public Shares in the Initial Public Offering). As a result of the underwriters’ election to fully exercise their over-allotment option, 375,000 Founder Shares are no longer subject to forfeiture.

The initial stockholders have agreed not to transfer, assign or sell any of the Founder Shares (except to certain permitted transferees) until, with respect to 50% of the Founder Shares, the earlier of (i) six months after the date of the consummation of a Business Combination, or (ii) the date on which the closing price of the Company’s common stock equals or exceeds $12.50 per share (as adjusted for stock splits, stock dividends, reorganizations and recapitalizations) for any 20 trading days within any 30-trading day period commencing after a Business Combination and, with respect to the remaining 50% of the Founder Shares, six months after the date of the consummation of a Business Combination, or earlier in each case, if, subsequent to a Business Combination, the Company consummates a subsequent liquidation, merger, stock exchange or other similar transaction which results in all of the Company’s stockholders having the right to exchange their common stock for cash, securities or other property.

Private Placement

Simultaneously with the closing of the Initial Public Offering, the Sponsor purchased an aggregate of 10,000,000 Private Warrants at a price of $0.50 per Private Warrant, for an aggregate purchase price of $5,000,000. Each Private Warrant is exercisable to purchase one-half of one share of common stock at a price of $11.50 per whole share. A portion of the proceeds from the Private Warrants were added to the proceeds from the Initial Public Offering held in the Trust Account. If the Company does not complete a Business Combination within the Combination Period, the proceeds from the sale of the Private Warrants will be used to fund the redemption of the Public Shares (subject to the requirements of applicable law), and the Private Warrants will expire worthless.

Advances from Related Party

In May 2019, the Sponsor advanced the Company an aggregate of $50,000 to cover expenses related to the Initial Public Offering. The advances were non-interest bearing and due on demand. The advances were repaid on May 15, 2019.

HEALTH SCIENCES ACQUISITIONS CORPORATION

NOTES TO CONDENSED FINANCIAL STATEMENTS

JUNE 30, 2019

(Unaudited)

Promissory Note – Related Party

On December 19, 2018, the Sponsor agreed to loan the Company an aggregate of up to $300,000 to cover expenses related to the Initial Public Offering (the “Promissory Note”). The Promissory Note was non-interest bearing and payable on the completion of the Initial Public Offering. The outstanding amount of $300,000 under the Promissory Note was repaid May 15, 2019.

Related Party Loans

In addition, in order to finance transaction costs in connection with a Business Combination, the initial stockholders or their affiliates may, but are not obligated to, loan the Company funds as may be required (“Working Capital Loans”). If the Company completes a Business Combination, the Company would repay the Working Capital Loans out of the proceeds of the Trust Account released to the Company. Otherwise, the Working Capital Loans would be repaid only out of funds held outside the Trust Account. In the event that a Business Combination does not close, the Company may use a portion of proceeds held outside the Trust Account to repay the Working Capital Loans, but no proceeds held in the Trust Account would be used to repay the Working Capital Loans. Except for the foregoing, the terms of such Working Capital Loans, if any, have not been determined and no written agreements exist with respect to such loans. The Working Capital Loans would either be repaid upon consummation of a Business Combination, without interest, or, at the lender’s discretion, up to $200,000 of such Working Capital Loans may be convertible into warrants of the post-Business Combination entity at a price of $0.50 per warrant. The warrants would be identical to the Private Warrants. There were no borrowings under the Working Capital Loans as of June 30, 2019.

Share Purchase Obligation

The Sponsor has entered into an agreement to purchase an aggregate of $20,000,000 of the Company’s shares of common stock in a private placement that would occur concurrently with the consummation of a Business Combination. The capital from such private placement may be used as part of the consideration to the sellers in a Business Combination, and any excess capital from such private placement would be used for working capital in the post-transaction company.

Administrative Support Agreement

The Company entered into an agreement whereby, commencing on the May 9, 2019 through the earlier of the Company’s consummation of a Business Combination and its liquidation, the Company will pay the Sponsor a total of $10,000 per month for office space, utilities and secretarial support. For the three and six months ended June 30, 2019, the Company incurred $20,000 in fees for these services.

NOTE 5. COMMITMENTS

Registration Rights

Pursuant to a registration rights agreement entered into on May 9, 2019, the holders of the Founder Shares, Private Warrants (including securities contained therein) and any shares that may be issued upon conversion of Working Capital Loans will be entitled to registration rights. The holders of a majority of these securities are entitled to make up to two demands that the Company register such securities. The holders of the majority of the Founder Shares can elect to exercise these registration rights at any time commencing three months prior to the date on which these shares of common stock are to be released from escrow. The holders of a majority of the Private Warrants or units issued in payment the Working Capital Loans may elect to exercise these registration rights at any time commencing on the date that the Company consummates a Business Combination. In addition, the holders have certain “piggy-back” registration rights with respect to registration statements filed subsequent to the consummation of a Business Combination. The Company will bear the expenses incurred in connection with the filing of any such registration statements.

Underwriting Agreement

The underwriters are entitled to a deferred fee of $0.35 per Unit, or $4,025,000 in the aggregate. The deferred fee will become payable to the underwriters from the amounts held in the Trust Account solely in the event that the Company completes a Business Combination, subject to the terms of the underwriting agreement.

HEALTH SCIENCES ACQUISITIONS CORPORATION

NOTES TO CONDENSED FINANCIAL STATEMENTS

JUNE 30, 2019

(Unaudited)

NOTE 6. STOCKHOLDER’S EQUITY

Common Stock — On May 9, 2019, the Company filed an Amended and Restated Certificate of Incorporation such that the Company is authorized to issue 30,000,000 shares of common stock with a par value of $0.0001 per share. Holders of common stock are entitled to one vote for each share. At June 30, 2019 and December 31, 2018, there were 3,545,057 and 2,875,000 shares of common stock issued and outstanding, excluding 10,829,943 and no shares of common stock subject to possible redemption, respectively. As a result of the underwriters’ election to fully exercise their over-allotment option, 375,000 Founder Shares are no longer subject to forfeiture.

Warrants — The Public Warrants will become exercisable on the later of (a) 30 days after the completion of the Company’s initial Business Combination or (b) May 14, 2020. The Public Warrants will expire five years after the completion of a Business Combination or earlier upon redemption or liquidation.

The Company will not be obligated to deliver any shares of common stock pursuant to the exercise of a warrant and will have no obligation to settle such warrant exercise unless a registration statement under the Securities Act with respect to the shares of common stock underlying the warrants is then effective and a prospectus relating thereto is current, subject to the Company satisfying its obligations with respect to registration. No warrant will be exercisable and the Company will not be obligated to issue shares of common stock upon exercise of a warrant unless the common stock issuable upon such warrant exercise has been registered, qualified or deemed to be exempt under the securities laws of the state of residence of the registered holder of the warrants.

The Company has agreed that, as soon as practicable, but in no event later than thirty (30) business days after the closing of a Business Combination, the Company will use its best efforts to file with the SEC a registration statement for the registration, under the Securities Act, of the shares of common stock issuable upon exercise of the warrants. The Company will use its best efforts to cause the same to become effective and to maintain the effectiveness of such registration statement, and a current prospectus relating thereto, until the expiration of the warrants in accordance with the provisions of the warrant agreement. In addition, the Company has agreed to use its best efforts to register the shares of common stock that are issuable upon exercise of the warrants under state blue sky laws, to the extent an exemption is not available. Notwithstanding the foregoing, if a registration statement covering the shares of common stock issuable upon exercise of the warrants has not been declared effective by the 90th business day following the closing of a Business Combination and during any period when the Company shall have failed to maintain an effective registration statement, warrant holders may, until such time as there is an effective registration statement, exercise the warrants on a cashless basis pursuant to the exemption provided by Section 3(a)(9) of the Securities Act.

Once the warrants become exercisable, the Company may redeem the Public Warrants:

	●	in whole and not in part;

	●	at a price of $0.01 per warrant;

	●	upon a minimum of 30 days’ prior written notice of redemption; and

	●	if, and only if, the last sale price of the Company’s common stock equals or exceeds $16.50 per share for any 20 trading days within a 30-trading day period ending on the third trading day prior to the date on which the Company sends the notice of redemption to the warrant holders.

The Private Warrants are identical to the Public Warrants underlying the Units sold in the Initial Public Offering, except that the Private Warrants and the common stock issuable upon the exercise of the Private Warrants will not be transferable, assignable or salable until after the completion of a Business Combination, subject to certain limited exceptions. Additionally, the Private Warrants will be exercisable on a cashless basis and be non-redeemable so long as they are held by the initial purchasers or their permitted transferees. If the Private Warrants are held by someone other than the initial purchasers or their permitted transferees, the Private Warrants will be redeemable by the Company and exercisable by such holders on the same basis as the Public Warrants.

If the Company calls the Public Warrants for redemption, management will have the option to require all holders that wish to exercise the Public Warrants to do so on a “cashless basis,” as described in the warrant agreement. The exercise price and number of shares of common stock issuable upon exercise of the warrants may be adjusted in certain circumstances including in the event of a stock dividend, or recapitalization, reorganization, merger or consolidation. However, the warrants will not be adjusted for issuance of common stock at a price below its exercise price. Additionally, in no event will the Company be required to net cash settle the warrants. If the Company is unable to complete a Business Combination within the Combination Period and the Company liquidates the funds held in the Trust Account, holders of warrants will not receive any of such funds with respect to their warrants, nor will they receive any distribution from the Company’s assets held outside of the Trust Account with the respect to such warrants. Accordingly, the warrants may expire worthless.

HEALTH SCIENCES ACQUISITIONS CORPORATION

NOTES TO CONDENSED FINANCIAL STATEMENTS

JUNE 30, 2019

(Unaudited)

NOTE 7. FAIR VALUE MEASUREMENTS

The Company classifies its U. S. Treasury and equivalent securities as held-to-maturity in accordance with ASC 320 “Investments - Debt and Equity Securities.” Held-to-maturity securities are those securities which the Company has the ability and intent to hold until maturity. Held-to-maturity treasury securities are recorded at amortized cost on the accompanying condensed balance sheets and adjusted for the amortization or accretion of premiums or discounts.

At June 30, 2019, assets held in the Trust Account were comprised of $8,783 in cash and $115,332,775 in U.S. Treasury Bills.

The gross holding losses and fair value of held-to-maturity securities at June 30, 2019 are as follows:

		Held-To-Maturity		Amortized Cost				Gross Holding Gain				Fair Value
June 30, 2019		U.S. Treasury Securities (Mature on 11/14/2019)		$	115,332,775			$	114,349			$	115,447,124

The fair value of the Company’s financial assets and liabilities reflects management’s estimate of amounts that the Company would have received in connection with the sale of the assets or paid in connection with the transfer of the liabilities in an orderly transaction between market participants at the measurement date. In connection with measuring the fair value of its assets and liabilities, the Company seeks to maximize the use of observable inputs (market data obtained from independent sources) and to minimize the use of unobservable inputs (internal assumptions about how market participants would price assets and liabilities). The following fair value hierarchy is used to classify assets and liabilities based on the observable inputs and unobservable inputs used in order to value the assets and liabilities:

	Level 1:	Quoted prices in active markets for identical assets or liabilities. An active market for an asset or liability is a market in which transactions for the asset or liability occur with sufficient frequency and volume to provide pricing information on an ongoing basis.

	Level 2:	Observable inputs other than Level 1 inputs. Examples of Level 2 inputs include quoted prices in active markets for similar assets or liabilities and quoted prices for identical assets or liabilities in markets that are not active.

	Level 3:	Unobservable inputs based on our assessment of the assumptions that market participants would use in pricing the asset or liability.

NOTE 8. SUBSEQUENT EVENTS

The Company evaluated subsequent events and transactions that occurred after the balance sheet date up to the date that the condensed financial statements were issued. Based on this review, the Company did not identify any subsequent events that would have required adjustment or disclosure in the condensed financial statements.

ITEM 2. MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS

References in this report (the “Quarterly Report”) to “we,” “us” or the “Company” refer to Health Sciences Acquisitions Corporation. References to our “management” or our “management team” refer to our officers and directors, references to the “Sponsor” refer to Health Sciences Holdings, LLC. The following discussion and analysis of the Company’s financial condition and results of operations should be read in conjunction with the financial statements and the notes thereto contained elsewhere in this Quarterly Report. Certain information contained in the discussion and analysis set forth below includes forward-looking statements that involve risks and uncertainties.

Special Note Regarding Forward-Looking Statements

This Quarterly Report includes “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Exchange Act that are not historical facts, and involve risks and uncertainties that could cause actual results to differ materially from those expected and projected. All statements, other than statements of historical fact included in this Form 10-Q including, without limitation, statements in this “Management’s Discussion and Analysis of Financial Condition and Results of Operations” regarding the Company’s financial position, business strategy and the plans and objectives of management for future operations, are forward-looking statements. Words such as “expect,” “believe,” “anticipate,” “intend,” “estimate,” “seek” and variations and similar words and expressions are intended to identify such forward-looking statements. Such forward-looking statements relate to future events or future performance, but reflect management’s current beliefs, based on information currently available. A number of factors could cause actual events, performance or results to differ materially from the events, performance and results discussed in the forward-looking statements. For information identifying important factors that could cause actual results to differ materially from those anticipated in the forward-looking statements, please refer to the Risk Factors section of the Company’s final prospectus for its Initial Public Offering filed with the U.S. Securities and Exchange Commission (the “SEC”). The Company’s securities filings can be accessed on the EDGAR section of the SEC’s website at www.sec.gov. Except as expressly required by applicable securities law, the Company disclaims any intention or obligation to update or revise any forward-looking statements whether as a result of new information, future events or otherwise.

Overview

We are a blank check company formed under the laws of the State of Delaware on December 6, 2018 for the purpose of effecting a merger, share exchange, asset acquisition, stock purchase, recapitalization, reorganization or similar Business Combination with one or more target businesses. Our efforts to identify a prospective target business will not be limited to any particular industry or geographic region, although we intend to focus our search on target businesses domiciled in North America or Europe that are developing assets in the biopharma and medical technology sectors. We intend to effectuate our Business Combination using cash from the proceeds of our Initial Public Offering and the sale of the Private Warrants that occurred simultaneously with the completion of our Initial Public Offering, our capital stock, debt or a combination of cash, stock and debt.

The issuance of additional shares in connection with an initial Business Combination to the owners of the target or other investors:

	●	may significantly dilute the equity interest of our investors who would not have pre-emption rights in respect of any such issuance;

	●	may subordinate the rights of holders of shares of common stock if we issue shares of preferred stock with rights senior to those afforded to our shares of common stock;

	●	will likely cause a change in control if a substantial number of our shares of common stock are issued, which may affect, among other things, our ability to use our net operating loss carry forwards, if any, and most likely will also result in the resignation or removal of our present officers and directors; and

	●	may adversely affect prevailing market prices for our securities.

Similarly, if we issue debt securities or otherwise incur significant debt to bank or other lenders or the owners of a target, it could result in:

	●	default and foreclosure on our assets if our operating revenues after our initial Business Combination are insufficient to pay our debt obligations;

	●	acceleration of our obligations to repay the indebtedness even if we have made all principal and interest payments when due if the debt security contains covenants that required the maintenance of certain financial ratios or reserves and we breach any such covenant without a waiver or renegotiation of that covenant;

	●	our immediate payment of all principal and accrued interest, if any, if the debt security is payable on demand;

	●	our inability to obtain additional financing, if necessary, if the debt security contains covenants restricting our ability to obtain additional financing while such security is outstanding; and

	●	limitations on our ability to borrow additional amounts for expenses, capital expenditures, acquisitions, debt service requirements, execution of our strategy and other purposes and other disadvantages compared to our competitors who have less debt.

We expect to continue to incur significant costs in the pursuit of our acquisition plans. We cannot assure you that our plans to complete a Business Combination will be successful.

Results of Operations

We have neither engaged in any operations nor generated any revenues to date. Our only activities from inception through May 14, 2019 were organizational activities and those necessary to prepare for the Initial Public Offering, described below. Subsequent to May 14, 2019, we have been seeking a target business to acquire. We do not expect to generate any operating revenues until after the completion of our Business Combination. We expect to generate non-operating income in the form of interest income on marketable securities held after the Initial Public Offering. We expect that we will incur increased expenses as a result of being a public company (for legal, financial reporting, accounting and auditing compliance), as well as for due diligence expenses in connection with completing a Business Combination.

For the three and six months ended June 30, 2019, we had net income of $182,749 and $182,299, respectively, which consists of interest income on marketable securities held in the Trust Account of $341,558, offset by operating costs of $92,342 and $92,792, respectively, and a provision for income taxes of $66,467.

Liquidity and Capital Resources

Until the consummation of the Initial Public Offering, the Company’s only source of liquidity was an initial purchase of common stock by the Sponsor and loans and advances from our Sponsor.

On May 14, 2019, we consummated the Initial Public Offering of 11,500,000 Units at a price of $10.00 per Unit, which includes the full exercise by the underwriters of the over-allotment option, at $10.00 per Unit, generating gross proceeds of $115,000,000. Simultaneously with the closing of the Initial Public Offering, we consummated the sale of 10,000,000 Private Warrants to the Sponsor at a price of $0.50 per warrant, generating gross proceeds of $5,000,000.

Following the Initial Public Offering, the exercise of the over-allotment option and the sale of the Private Warrants, a total of $115,000,000 was placed in the Trust Account. We incurred $6,907,415 in transaction costs, including $2,300,000 of underwriting fees, $4,025,000 of deferred underwriting fees and $582,415 of other costs.

For the six months ended June 30, 2019, cash used in operating activities was $230,733. Net income of $182,299 was offset by interest earned on marketable securities held in the Trust Account of $341,558. Changes in operating assets and liabilities used $71,474 of cash from operating activities.

As of June 30, 2019, we had cash and marketable securities held in the Trust Account of $115,341,558. We intend to use substantially all of the funds held in the Trust Account, including any amounts representing interest earned on the Trust Account (less deferred underwriting commissions and income taxes payable), to complete our Business Combination. To the extent that our capital stock or debt is used, in whole or in part, as consideration to complete our Business Combination, the remaining proceeds held in the Trust Account will be used as working capital to finance the operations of the target business or businesses, make other acquisitions and pursue our growth strategies.

As of June 30, 2019, we had $1,911,852 of cash held outside of the Trust Account. We will use these funds primarily to identify and evaluate target businesses, perform business due diligence on prospective target businesses, travel to and from the offices, plants or similar locations of prospective target businesses or their representatives or owners, review corporate documents and material agreements of prospective target businesses, and structure, negotiate and complete a Business Combination.

In order to fund working capital deficiencies or finance transaction costs in connection with a Business Combination, the initial stockholders or their affiliates may, but are not obligated to, loan us funds as may be required. If we complete a Business Combination, we would repay such loaned amounts. In the event that a Business Combination does not close, we may use a portion of the working capital held outside the Trust Account to repay such loaned amounts but no proceeds from our Trust Account would be used for such repayment. Up to $200,000 of such loans may be convertible into warrants identical to the Private Warrants, at a price of $0.50 per warrant at the option of the lender.

We do not believe we will need to raise additional funds in order to meet the expenditures required for operating our business. However, if our estimate of the costs of identifying a target business, undertaking in-depth due diligence and negotiating a Business Combination are less than the actual amount necessary to do so, we may have insufficient funds available to operate our business prior to our Business Combination. Moreover, we may need to obtain additional financing either to complete our Business Combination or because we become obligated to redeem a significant number of our public shares upon consummation of our Business Combination, in which case we may issue additional securities or incur debt in connection with such Business Combination. Subject to compliance with applicable securities laws, we would only complete such financing simultaneously with the completion of our Business Combination. If we are unable to complete our Business Combination because we do not have sufficient funds available to us, we will be forced to cease operations and liquidate the Trust Account. In addition, following our Business Combination, if cash on hand is insufficient, we may need to obtain additional financing in order to meet our obligations.

Off-balance sheet financing arrangements

We have no obligations, assets or liabilities, which would be considered off-balance sheet arrangements as of June 30, 2019. We do not participate in transactions that create relationships with unconsolidated entities or financial partnerships, often referred to as variable interest entities, which would have been established for the purpose of facilitating off-balance sheet arrangements. We have not entered into any off-balance sheet financing arrangements, established any special purpose entities, guaranteed any debt or commitments of other entities, or purchased any non-financial assets.

Contractual obligations

We do not have any long-term debt, capital lease obligations, operating lease obligations or long-term liabilities, other than an agreement to pay the Sponsor a monthly fee of $10,000 for office space, utilities and secretarial support to the Company. We began incurring these fees on May 9, 2019 and will continue to incur these fees monthly until the earlier of the completion of the Business Combination and the Company’s liquidation.

Critical Accounting Policies

The preparation of financial statements and related disclosures in conformity with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, disclosure of contingent assets and liabilities at the date of the financial statements, and income and expenses during the periods reported. Actual results could materially differ from those estimates. We have identified the following critical accounting policies:

Common stock subject to possible redemption

We account for our common stock subject to possible redemption in accordance with the guidance in Accounting Standards Codification (“ASC”) Topic 480 “Distinguishing Liabilities from Equity.” Common stock subject to mandatory redemption is classified as a liability instrument and is measured at fair value. Conditionally redeemable common stock (including common stock that features redemption rights that are either within the control of the holder or subject to redemption upon the occurrence of uncertain events not solely within our control) is classified as temporary equity. At all other times, common stock is classified as stockholders’ equity. Our common stock features certain redemption rights that are considered to be outside of our control and subject to occurrence of uncertain future events. Accordingly, common stock subject to possible redemption is presented as temporary equity, outside of the stockholders’ equity section of our balance sheets.

Net loss per common share

We apply the two-class method in calculating earnings per share. Net income per common share, basic and diluted for Class A redeemable common stock is calculated by dividing the interest income earned on the Trust Account, net of applicable franchise and income taxes, by the weighted average number of Class A redeemable common stock outstanding for the period. Net loss per common share, basic and diluted for Class A and Class B non-redeemable common stock is calculated by dividing the net income, less income attributable to Class A redeemable common stock, by the weighted average number of Class A and Class B non-redeemable common stock outstanding for the period.

Recent accounting pronouncements

Management does not believe that any recently issued, but not yet effective, accounting standards, if currently adopted, would have a material effect on our condensed financial statements.

ITEM 3. QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK

As of June 30, 2019, we were not subject to any market or interest rate risk. Following the consummation of our Initial Public Offering, the net proceeds of our Initial Public Offering, including amounts in the Trust Account, have been invested in U.S. government treasury bills, notes or bonds with a maturity of 180 days or less or in certain money market funds that invest solely in U.S. treasuries. Due to the short-term nature of these investments, we believe there will be no associated material exposure to interest rate risk.

ITEM 4. CONTROLS AND PROCEDURES

Disclosure controls and procedures are controls and other procedures that are designed to ensure that information required to be disclosed in our reports filed or submitted under the Exchange Act is recorded, processed, summarized and reported within the time periods specified in the SEC’s rules and forms. Disclosure controls and procedures include, without limitation, controls and procedures designed to ensure that information required to be disclosed in our reports filed or submitted under the Exchange Act is accumulated and communicated to our management, including our Chief Executive Officer and Chief Financial Officer, to allow timely decisions regarding required disclosure.

Evaluation of Disclosure Controls and Procedures

As required by Rules 13a-15 and 15d-15 under the Exchange Act, our Chief Executive Officer and Chief Financial Officer carried out an evaluation of the effectiveness of the design and operation of our disclosure controls and procedures as of June 30, 2019. Based upon their evaluation, our Chief Executive Officer and Chief Financial Officer concluded that our disclosure controls and procedures (as defined in Rules 13a-15 (e) and 15d-15 (e) under the Exchange Act) were effective.

Changes in Internal Control Over Financial Reporting

During the most recently completed fiscal quarter, there has been no change in our internal control over financial reporting that has materially affected, or is reasonably likely to materially affect, our internal control over financial reporting.

PART II - OTHER INFORMATION

ITEM 1. LEGAL PROCEEDINGS.

None.

ITEM 1A. RISK FACTORS.

Factors that could cause our actual results to differ materially from those in this Quarterly Report are any of the risks described in our final prospectus for our Initial Public Offering filed with the SEC on May 10, 2019. Any of these factors could result in a significant or material adverse effect on our results of operations or financial condition. Additional risk factors not presently known to us or that we currently deem immaterial may also impair our business or results of operations. As of the date of this Quarterly Report, there have been no material changes to the risk factors disclosed in our final prospectus for our Initial Public Offering filed with the SEC on May 10, 2019, except we may disclose changes to such factors or disclose additional factors from time to time in our future filings with the SEC.

ITEM 2. UNREGISTERED SALES OF EQUITY SECURITIES AND USE OF PROCEEDS.

On May 14, 2019, we consummated our Initial Public Offering of 115,000,000 Units, which includes the full exercise by the underwriters of the over-allotment option. The Units were sold at an offering price of $10.00 per Unit, generating total gross proceeds of $115,000,000. Chardan Capital Markets LLC and UBS Securities LLC acted as joint book running managers. The securities sold in the offering were registered under the Securities Act on a registration statement on Form S-1 (No. 333-230893). The SEC declared the registration statement effective on May 9, 2019.

Simultaneously with the consummation of the Initial Public Offering and the over-allotment option, we consummated a private placement of 10,000,000 Private Warrants to our Sponsor at a price of $0.50 per warrant, generating total proceeds of $5,000,000. Such securities were issued pursuant to the exemption from registration contained in Section 4(a)(2) of the Securities Act.

The Private Warrants are the same as the Public Warrants underlying the Units sold in the Initial Public Offering, except that the Private Warrants are not transferable, assignable or salable until after the completion of a Business Combination, subject to certain limited exceptions. Additionally, the Private Warrants are exercisable on a cashless basis and are non-redeemable so long as they are held by the initial purchasers or their permitted transferees.

Of the gross proceeds received from the sale of the Private Warrants, the Initial Public Offering and the full exercise of the over-allotment option, $115,000,000 was placed in the Trust Account.

We paid a total of $2,300,000 underwriting discounts and commissions and $582,415 for other costs and expenses related to the Initial Public Offering. In addition, the underwriters agreed to defer $4,025,000 in underwriting discounts and commissions.

For a description of the use of the proceeds generated in our Initial Public Offering, see Part I, Item 2 of this Form 10-Q.

ITEM 3. DEFAULTS UPON SENIOR SECURITIES.

None.

ITEM 4. MINE SAFETY DISCLOSURES.

Not applicable.

ITEM 5. OTHER INFORMATION.

None.

ITEM 6. EXHIBITS.

The following exhibits are filed as part of, or incorporated by reference into, this Quarterly Report on Form 10-Q.

No.		Description of Exhibit
31.1*		Certification of Principal Executive Officer Pursuant to Securities Exchange Act Rules 13a-14(a) and 15(d)-14(a), as adopted Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002
31.2*		Certification of Principal Financial Officer Pursuant to Securities Exchange Act Rules 13a-14(a) and 15(d)-14(a), as adopted Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002
32.1**		Certification of Principal Executive Officer Pursuant to 18 U.S.C. Section 1350, as adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002
32.2**		Certification of Principal Financial Officer Pursuant to 18 U.S.C. Section 1350, as adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002
101.INS*		XBRL Instance Document
101.CAL*		XBRL Taxonomy Extension Calculation Linkbase Document
101.SCH*		XBRL Taxonomy Extension Schema Document
101.DEF*		XBRL Taxonomy Extension Definition Linkbase Document
101.LAB*		XBRL Taxonomy Extension Labels Linkbase Document
101.PRE*		XBRL Taxonomy Extension Presentation Linkbase Document

*	Filed herewith.
**	Furnished.

SIGNATURES

Pursuant to the requirements of Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

	HEALTH SCIENCES ACQUISITIONS CORPORATION

Date: August 12, 2019		/s/ Roderick Wong
	Name:	Roderick Wong, MD
	Title:	President and Chief Executive Officer
		(Principal Executive Officer)

Date: August 12, 2019		/s/ Naveen Yalamanchi
	Name:	Naveen Yalamanchi, MD
	Title:	Executive Vice President and Chief Financial Officer (Principal Accounting and Financial Officer)

EX-31.1 2 f10q0619ex31-1_health.htm CERTIFICATION

Exhibit 31.1

CERTIFICATIONS

I, Roderick Wong, certify that:

I have reviewed this Quarterly Report on Form 10-Q of Health Sciences Acquisitions Corporation;

Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

The registrant’s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) for the registrant and have:

Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

(Paragraph omitted pursuant to SEC Release Nos. 33-8238/34-47986 and 33-8392/34-49313);

Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and

The registrant’s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):

(a)

All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and

(b)

Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

Date: August 12, 2019

By:

/s/ Roderick Wong

Roderick Wong, MD

President and Chief Executive Officer

(Principal Executive Officer)

EX-31.2 3 f10q0619ex31-2_health.htm CERTIFICATION

Exhibit 31.2

CERTIFICATIONS

I, Naveen Yalamanchi, certify that:

I have reviewed this Quarterly Report on Form 10-Q of Health Sciences Acquisitions Corporation;

(Paragraph omitted pursuant to SEC Release Nos. 33-8238/34-47986 and 33-8392/34-49313);

(a)

(b)

Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

Date: August 12, 2019

By:

/s/ Naveen Yalamanchi

Naveen Yalamanchi, MD

Executive Vice President and Chief Financial Officer

(Principal Accounting and Financial Officer)

EX-32.1 4 f10q0619ex32-1_health.htm CERTIFICATION

Exhibit 32.1

CERTIFICATION PURSUANT TO

18 U.S.C. SECTION 1350,

AS ADDED BY

SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

In connection with the Quarterly Report of Health Sciences Acquisitions Corporation (the “Company”) on Form 10-Q for the quarterly period ended June 30, 2019, as filed with the Securities and Exchange Commission (the “Report”), I, Roderick Wong, Chief Executive Officer of the Company, certify, pursuant to 18 U.S.C. §1350, as added by §906 of the Sarbanes-Oxley Act of 2002, that:

The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and

To my knowledge, the information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company as of and for the period covered by the Report.

Date: August 12, 2019

By:

/s/ Roderick Wong

Roderick Wong, MD

President and Chief Executive Officer

(Principal Executive Officer)

EX-32.2 5 f10q0619ex32-2_health.htm CERTIFICATION

Exhibit 32.2

CERTIFICATION PURSUANT TO

18 U.S.C. SECTION 1350,

AS ADDED BY

SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

In connection with the Quarterly Report of Health Sciences Acquisitions Corporation (the “Company”) on Form 10-Q for the quarterly period ended June 30, 2019, as filed with the Securities and Exchange Commission (the “Report”), I, Naveen Yalamanchi, Chief Financial Officer of the Company, certify, pursuant to 18 U.S.C. §1350, as added by §906 of the Sarbanes-Oxley Act of 2002, that:

The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and

Date: August 12, 2019

By:

/s/ Naveen Yalamanchi

Naveen Yalamanchi, MD

Executive Vice President and Chief Financial Officer

(Principal Accounting and Financial Officer)

EX-101.INS 6 hsac-20190630.xml XBRL INSTANCE FILE 0001764013 2019-01-01 2019-06-30 0001764013 2019-06-30 0001764013 2018-12-31 0001764013 us-gaap:CommonStockMember 2018-12-31 0001764013 us-gaap:CommonStockMember 2019-06-30 0001764013 us-gaap:AdditionalPaidInCapitalMember 2018-12-31 0001764013 us-gaap:AdditionalPaidInCapitalMember 2019-06-30 0001764013 us-gaap:RetainedEarningsMember 2018-12-31 0001764013 us-gaap:RetainedEarningsMember 2019-06-30 0001764013 us-gaap:IPOMember 2019-01-01 2019-06-30 0001764013 us-gaap:IPOMember 2019-06-30 0001764013 HSAC:FounderMember 2018-01-01 2018-12-31 0001764013 us-gaap:PrivatePlacementMember 2019-01-01 2019-06-30 0001764013 us-gaap:PrivatePlacementMember 2019-06-30 0001764013 us-gaap:IPOMember 2019-05-01 2019-05-31 0001764013 us-gaap:IPOMember 2018-12-01 2018-12-19 0001764013 2019-05-09 0001764013 2019-04-01 2019-06-30 0001764013 us-gaap:CommonStockMember 2019-01-01 2019-03-31 0001764013 us-gaap:CommonStockMember 2019-04-01 2019-06-30 0001764013 us-gaap:CommonStockMember 2019-03-31 0001764013 us-gaap:AdditionalPaidInCapitalMember 2019-01-01 2019-03-31 0001764013 us-gaap:AdditionalPaidInCapitalMember 2019-04-01 2019-06-30 0001764013 us-gaap:AdditionalPaidInCapitalMember 2019-03-31 0001764013 us-gaap:RetainedEarningsMember 2019-01-01 2019-03-31 0001764013 us-gaap:RetainedEarningsMember 2019-04-01 2019-06-30 0001764013 us-gaap:RetainedEarningsMember 2019-03-31 0001764013 2019-01-01 2019-03-31 0001764013 2019-03-31 0001764013 us-gaap:IPOMember 2019-05-14 0001764013 us-gaap:IPOMember 2019-05-01 2019-05-14 0001764013 us-gaap:PrivatePlacementMember 2019-05-01 2019-05-14 0001764013 us-gaap:PrivatePlacementMember 2019-05-14 0001764013 2019-05-01 2019-05-14 0001764013 2019-05-14 0001764013 2019-05-01 2019-05-09 0001764013 2019-08-12 iso4217:USD xbrli:shares iso4217:USD xbrli:shares xbrli:pure Health Sciences Acquisitions Corp 0001764013 10-Q 2019-06-30 false --12-31 true Non-accelerated Filer true Q2 2019

80000

117415503

405000

24600

448

300000

91067

380448

80000

355

288

4817800

24712

181851

-448

117415503

405000

0.0001

30000000

3545057

2875000

3545057

2875000

182299

182749

-450

182749

-450

11500000

0.02

2875000

10000000

11500000

10.00

6907415

115000000

11500000

10000000

10.00

0.50

5000000

10750000

250000

The Founder Shares included an aggregate of up to 375,000 shares subject to forfeiture to the extent that the underwriters’ over-allotment option was not exercised in full or in part, so that the initial stockholders would own, on an as-converted basis, 20% of the Company’s issued and outstanding shares after the Initial Public Offering (assuming the initial stockholders did not purchase any Public Shares in the Initial Public Offering). As a result of the underwriters’ election to fully exercise their over-allotment option, 375,000 Founder Shares are no longer subject to forfeiture.

25000

0.50

5000000

Each Private Warrant is exercisable to purchase one-half of one share of common stock at a price of $11.50 per whole share.

50000

300000

200000

20000000

Once the warrants become exercisable, the Company may redeem the Public Warrants: ● in whole and not in part; ● at a price of $0.01 per warrant; ● upon a minimum of 30 days’ prior written notice of redemption; and ● if, and only if, the last sale price of the Company’s common stock equals or exceeds $16.50 per share for any 20 trading days within a 30-trading day period ending on the third trading day prior to the date on which the Company sends the notice of redemption to the warrant holders. The Public Warrants will become exercisable on the later of (a) 30 days after the completion of the Company’s initial Business Combination or (b) May 14, 2020. The Public Warrants will expire five years after the completion of a Business Combination or earlier upon redemption or liquidation.

5000001

1.00

0.20

0.80

0.50

10.00 001-38906 true Yes DE Yes

2073945

162093

115341558

4116067

380448

4025000

66467

108299430

10829943

67742

-92792

-92342

341558

248766

249216

66467

2875000 2875000 -0.02 -0.02 375000 375000

5000006

24552

288

355

24712

4817800

-448

181851

288

24712

-898

24102

2875000

3545057

2875000

11500000 10000000 108092585 1150 108091435 11500000 5000000 5000000 -108299430 -1083 -108298347 -10829943 -341588

-230733

66467

24152

162093

-115000000

115000000

116817585

582415

-300000

-50000

112700000

1911852

325000

1586852

183150 108116280 4025000

NOTE 1. DESCRIPTION OF ORGANIZATION AND BUSINESS OPERATIONS   Health Sciences Acquisitions Corporation (the “Company”) was incorporated in Delaware on December 6, 2018. The Company was formed for the purpose of effecting a merger, share exchange, asset acquisition, stock purchase, recapitalization, reorganization or similar business combination with one or more businesses (the “Business Combination”).   Although the Company is not limited to a particular or geographic region for purposes of consummating a Business Combination, the Company intends to focus on businesses in the healthcare and healthcare-related industries in North America or Europe. The Company is an emerging growth company and, as such, the Company is subject to all of the risks associated with emerging growth companies.   As of June 30, 2019, the Company had not commenced any operations, other than searching for a target business. All activity for the period from December 6, 2018 (inception) through June 30, 2019 relates to the Company’s formation, the initial public offering (“Initial Public Offering”), which is described below, and identifying a target company for a Business Combination. The Company will not generate any operating revenues until after the completion of its initial Business Combination, at the earliest. The Company generates non-operating income in the form of interest income from the proceeds derived from the Initial Public Offering.   The registration statement for the Company’s Initial Public Offering was declared effective on May 9, 2019. On May 14, 2019, the Company consummated the Initial Public Offering of 11,500,000 units (the “Units” and, with respect to the shares common stock included in the Units sold, the “Public Shares”), which includes the full exercise by the underwriters of the over-allotment option, at $10.00 per Unit, generating gross proceeds of $115,000,000, which is described in Note 3.   Simultaneously with the closing of the Initial Public Offering, the Company consummated the sale of 10,000,000 warrants (the “Private Warrants”) at a price of $0.50 per Private Warrant in a private placement to Health Sciences Holdings, LLC, a Delaware limited liability company (the “Sponsor”), generating gross proceeds of $5,000,000, which is described in Note 4.   Transaction costs amounted to $6,907,415, consisting of $2,300,000 of underwriting fees, $4,025,000 of deferred underwriting fees and $582,415 of other offering costs. At June 30, 2019, $1,911,852 of cash was held outside of the Trust Account (as defined below) and is available for working capital purposes.   Following the closing of the Initial Public Offering on May 14, 2019, an amount of $115,000,000 ($10.00 per Unit) from the net proceeds of the sale of the Units in the Initial Public Offering and the sale of the Private Warrants was placed in a trust account (“Trust Account”) which will be invested in U.S. government securities, within the meaning set forth in Section 2(a)(16) of the Investment Company Act of 1940, as amended (the “Investment Company Act”), with a maturity of 180 days or less or in any open-ended investment company that holds itself out as a money market fund meeting the conditions of Rule 2a-7 of the Investment Company Act, as determined by the Company, until the earlier of: (i) the completion of a Business Combination or (ii) the distribution of the Trust Account, as described below.   The Company’s management has broad discretion with respect to the specific application of the net proceeds of the Initial Public Offering and the sale of the Private Warrants, although substantially all of the net proceeds are intended to be applied generally toward consummating a Business Combination. The Company’s initial Business Combination must be with one or more target businesses that together have a fair market value of at least 80% of the assets held in the Trust Account (excluding the deferred underwriting fees and taxes payable on the income earned on the Trust Account) at the time of the agreement to enter into a Business Combination. The Company will only complete a Business Combination if the post-transaction Company owns or acquires 50% or more of the outstanding voting securities of the target or otherwise acquires a controlling interest in the target sufficient for it not to be required to register as an investment company under the Investment Company Act 1940, as amended (the “Investment Company Act”). There is no assurance that the Company will be able to complete a Business Combination successfully.   The Company will provide its holders of the outstanding Public Shares (the “public stockholders”) with the opportunity to convert all or a portion of their Public Shares upon the completion of a Business Combination either (i) in connection with a stockholder meeting called to approve the Business Combination or (ii) by means of a tender offer. The decision as to whether the Company will seek stockholder approval of a Business Combination or conduct a tender offer will be made by the Company, solely in its discretion. The public stockholders will be entitled to convert their Public Shares for a pro rata portion of the amount then in the Trust Account (initially $10.00 per Public Share, plus any pro rata interest earned on the funds held in the Trust Account and not previously released to the Company to pay its income and franchise tax obligations). There will be no redemption rights upon the completion of a Business Combination with respect to the Company’s warrants.   The Company will proceed with a Business Combination if the Company has net tangible assets of at least $5,000,001 upon such consummation of a Business Combination and, if the Company seeks stockholder approval, a majority of the shares voted are voted in favor of the Business Combination. If a stockholder vote is not required by law and the Company does not decide to hold a stockholder vote for business or other legal reasons, the Company will, pursuant to its Amended and Restated Certificate of Incorporation, conduct the redemptions pursuant to the tender offer rules of the U.S. Securities and Exchange Commission (“SEC”) and file tender offer documents with the SEC prior to completing a Business Combination. If, however, stockholder approval of the transactions is required by law, or the Company decides to obtain stockholder approval for business or legal reasons, the Company will offer to redeem shares in conjunction with a proxy solicitation pursuant to the proxy rules and not pursuant to the tender offer rules. If the Company seeks stockholder approval in connection with a Business Combination, the Company’s Sponsor, officers and directors (the “initial stockholders”) have agreed (i) to vote their Founder Shares (as defined in Note 4) and any Public Shares acquired in or after the Initial Public Offering in favor of a Business Combination, (ii) not to convert any shares owned by them in connection therewith and (iii) not to sell any of their shares to the Company in a tender offer. Additionally, each public stockholder may elect to convert their Public Shares irrespective of whether they vote for or against the proposed transaction.   Notwithstanding the foregoing, if the Company seeks stockholder approval of a Business Combination and it does not conduct conversions pursuant to the tender offer rules, the Amended and Restated Certificate of Incorporation provides that a public stockholder, together with any affiliate of such stockholder or any other person with whom such stockholder is acting in concert or as a “group” (as defined under Section 13 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”)), will be restricted from converting its shares with respect to more than an aggregate of 20% or more of the Public Shares, without the prior consent of the Company.   The initial stockholders have agreed (a) to waive their redemption rights with respect to their Founder Shares and Public Shares held by them in connection with the completion of a Business Combination and (b) not to propose, or vote in favor of, an amendment to the Amended and Restated Certificate of Incorporation that would affect the substance or timing of the Company’s obligation to redeem 100% of its Public Shares if the Company does not complete a Business Combination, unless the Company provides the public stockholders with the opportunity to redeem their Public Shares in conjunction with any such amendment.   The Company will have until May 14, 2021 to complete a Business Combination (the “Combination Period”). If the Company is unable to complete a Business Combination within the Combination Period, the Company will (i) cease all operations except for the purpose of winding up, (ii) as promptly as reasonably possible but not more than ten business days thereafter, redeem 100% of the outstanding Public Shares for a pro rata portion of the funds held in the Trust Account, which redemption will completely extinguish public stockholders’ rights as stockholders (including the right to receive further liquidating distributions, if any), subject to applicable law, and (iii) as promptly as reasonably possible following such redemption, subject to the approval of the Company’s remaining stockholders and the Company’s board of directors, dissolve and liquidate, subject in each case to the Company’s obligations under Delaware law to provide for claims of creditors and the requirements of other applicable law. There will be no redemption rights or liquidating distributions with respect to the Company’s warrants, which will expire worthless if the Company fails to complete a Business Combination within the Combination Period.   The initial stockholders have agreed to waive their liquidation rights with respect to the Founder Shares and Private Shares if the Company fails to complete a Business Combination within the Combination Period. However, if the Sponsor, officers and directors acquire Public Shares in or after the Initial Public Offering, such Public Shares will be entitled to liquidating distributions from the Trust Account if the Company fails to complete a Business Combination within the Combination Period. The underwriters have agreed to waive their rights to their deferred underwriting commissions (see Note 5) held in the Trust Account in the event the Company does not complete a Business Combination within the Combination Period and, in such event, such amounts will be included with the funds held in the Trust Account that will be available to fund the redemption of the Public Shares. In the event of such distribution, it is possible that the per share value of the assets remaining available for distribution will be less than the Initial Public Offering price per Unit ($10.00).   In order to protect the amounts held in the Trust Account, the initial stockholders have agreed to be liable to the Company if and to the extent any claims by a vendor for services rendered or products sold to the Company, or a prospective target business with which the Company has discussed entering into a transaction agreement, reduce the amounts in the Trust Account to below $10.00 per Public Share, except as to any claims by a third party who executed a valid and enforceable agreement with us waiving any right, title, interest or claim of any kind they may have in or to any monies held in the trust account and except as to any claims under our indemnity of the underwriters from our Initial Public Offering against certain liabilities, including liabilities under the Securities Act of 1933, as amended (the “Securities Act”). Moreover, in the event that an executed waiver is deemed to be unenforceable against a third party, the initial stockholders will not be responsible to the extent of any liability for such third-party claims. The Company will seek to reduce the possibility that the initial stockholders will have to indemnify the Trust Account due to claims of creditors by endeavoring to have all vendors, service providers (except the Company’s independent registered accounting firm), prospective target businesses or other entities with which the Company does business, execute agreements with the Company waiving any right, title, interest or claim of any kind in or to monies held in the Trust Account.

2300000

4025000 582415 115000000

6907415

Recently issued accounting standards   Management does not believe that any recently issued, but not yet effective, accounting pronouncements, if currently adopted, would have a material effect on the Company's condensed financial statements.

Financial instruments   The fair value of the Company's assets and liabilities, which qualify as financial instruments under ASC Topic 820, "Fair Value Measurements and Disclosures," approximates the carrying amounts represented in the accompanying condensed balance sheets, primarily due to their short-term nature.

Concentration of credit risk   Financial instruments that potentially subject the Company to concentration of credit risk consist of a cash account in a financial institution, which, at times, may exceed the Federal Depository Insurance Coverage of $250,000. At June 30, 2019 and December 31, 2018, the Company had not experienced losses on this account and management believes the Company is not exposed to significant risks on such account.

Offering costs   Offering costs consist of legal, accounting, underwriting fees and other costs incurred through the balance sheet date that were directly related to the Initial Public Offering. Offering costs amounting to $6,907,415 were charged to stockholders' equity upon the completion of the Initial Public Offering.

Common stock subject to possible redemption   The Company accounts for its common stock subject to possible redemption in accordance with the guidance in Accounting Standards Codification ("ASC") Topic 480 "Distinguishing Liabilities from Equity." Common stock subject to mandatory redemption is classified as a liability instrument and is measured at fair value. Conditionally redeemable common stock (including common stock that features redemption rights that is either within the control of the holder or subject to redemption upon the occurrence of uncertain events not solely within the Company's control) is classified as temporary equity. At all other times, common stock is classified as stockholders' equity. The Company's common stock features certain redemption rights that are considered to be outside of the Company's control and subject to occurrence of uncertain future events. Accordingly, at June 30, 2019, common stock subject to possible redemption is presented as temporary equity, outside of the stockholders' equity section of the Company's condensed balance sheet.

Use of estimates   The preparation of condensed financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the condensed financial statements and the reported amounts of revenues and expenses during the reporting period.   Making estimates requires management to exercise significant judgment. It is at least reasonably possible that the estimate of the effect of a condition, situation or set of circumstances that existed at the date of the financial statement, which management considered in formulating its estimate, could change in the near term due to one or more future confirming events. Accordingly, the actual results could differ significantly from those estimates.

Emerging growth company   The Company is an "emerging growth company," as defined in Section 2(a) of the Securities Act, as modified by the Jumpstart Our Business Startups Act of 2012 (the "JOBS Act"), and it may take advantage of certain exemptions from various reporting requirements that are applicable to other public companies that are not emerging growth companies including, but not limited to, not being required to comply with the independent registered public accounting firm attestation requirements of Section 404 of the Sarbanes-Oxley Act, reduced disclosure obligations regarding executive compensation in its periodic reports and proxy statements, and exemptions from the requirements of holding a nonbinding advisory vote on executive compensation and stockholder approval of any golden parachute payments not previously approved.   Further, Section 102(b)(1) of the JOBS Act exempts emerging growth companies from being required to comply with new or revised financial accounting standards until private companies (that is, those that have not had a Securities Act registration statement declared effective or do not have a class of securities registered under the Exchange Act) are required to comply with the new or revised financial accounting standards. The JOBS Act provides that a company can elect to opt out of the extended transition period and comply with the requirements that apply to non-emerging growth companies but any such election to opt out is irrevocable. The Company has elected not to opt out of such extended transition period, which means that when a standard is issued or revised and it has different application dates for public or private companies, the Company, as an emerging growth company, can adopt the new or revised standard at the time private companies adopt the new or revised standard. This may make comparison of the Company's financial statements with another public company which is neither an emerging growth company nor an emerging growth company which has opted out of using the extended transition period difficult or impossible because of the potential differences in accounting standards used.

Basis of presentation   The accompanying unaudited condensed financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America ("GAAP") for interim financial information and in accordance with the instructions to Form 10-Q and Article 8 of Regulation S-X of the SEC. Certain information or footnote disclosures normally included in financial statements prepared in accordance with GAAP have been condensed or omitted, pursuant to the rules and regulations of the SEC for interim financial reporting. Accordingly, they do not include all the information and footnotes necessary for a complete presentation of financial position, results of operations, or cash flows. In the opinion of management, the accompanying unaudited condensed financial statements include all adjustments, consisting of a normal recurring nature, which are necessary for a fair presentation of the financial position, operating results and cash flows for the periods presented.   The accompanying unaudited condensed financial statements should be read in conjunction with the Company's <a href="http://www.sec.gov/Archives/edgar/data/1764013/000161577419007495/s118185_424b4.htm">prospectus</a> for its Initial Public Offering as filed with the SEC on May 10, 2019, as well as the Company's Current Report on <a href="http://www.sec.gov/Archives/edgar/data/1764013/000161577419007917/s118326_8k.htm">Form 8-K</a>, as filed with the SEC on May 15, 2019. The interim results for the three and six months ended June 30, 2019 are not necessarily indicative of the results to be expected for the year ended December 31, 2019 or for any future periods.

92000 NOTE 3. INITIAL PUBLIC OFFERING   Pursuant to the Initial Public Offering, the Company sold 11,500,000 Units at a purchase price of $10.00 per Unit, which includes the full exercise by the underwriters of their option to purchase an additional 1,500,000 Units at $10.00 per Unit. Each Unit consists of one share of common stock and one redeemable warrant ("Public Warrant"). Each Public Warrant entitles the holder to purchase one-half of one share of common stock at a price of $11.50 per whole share, subject to adjustment (see Note 6).

NOTE 4. RELATED PARTY TRANSACTIONS   Founder Shares   In December 2018, the Sponsor purchased 2,875,000 shares (the "Founder Shares") of the Company's common stock for an aggregate price of $25,000. The Founder Shares included an aggregate of up to 375,000 shares subject to forfeiture to the extent that the underwriters' over-allotment option was not exercised in full or in part, so that the initial stockholders would own, on an as-converted basis, 20% of the Company's issued and outstanding shares after the Initial Public Offering (assuming the initial stockholders did not purchase any Public Shares in the Initial Public Offering). As a result of the underwriters' election to fully exercise their over-allotment option, 375,000 Founder Shares are no longer subject to forfeiture.   The initial stockholders have agreed not to transfer, assign or sell any of the Founder Shares (except to certain permitted transferees) until, with respect to 50% of the Founder Shares, the earlier of (i) six months after the date of the consummation of a Business Combination, or (ii) the date on which the closing price of the Company's common stock equals or exceeds $12.50 per share (as adjusted for stock splits, stock dividends, reorganizations and recapitalizations) for any 20 trading days within any 30-trading day period commencing after a Business Combination and, with respect to the remaining 50% of the Founder Shares, six months after the date of the consummation of a Business Combination, or earlier in each case, if, subsequent to a Business Combination, the Company consummates a subsequent liquidation, merger, stock exchange or other similar transaction which results in all of the Company's stockholders having the right to exchange their common stock for cash, securities or other property.    Private Placement   Simultaneously with the closing of the Initial Public Offering, the Sponsor purchased an aggregate of 10,000,000 Private Warrants at a price of $0.50 per Private Warrant, for an aggregate purchase price of $5,000,000. Each Private Warrant is exercisable to purchase one-half of one share of common stock at a price of $11.50 per whole share. A portion of the proceeds from the Private Warrants were added to the proceeds from the Initial Public Offering held in the Trust Account. If the Company does not complete a Business Combination within the Combination Period, the proceeds from the sale of the Private Warrants will be used to fund the redemption of the Public Shares (subject to the requirements of applicable law), and the Private Warrants will expire worthless.   Advances from Related Party   In May 2019, the Sponsor advanced the Company an aggregate of $50,000 to cover expenses related to the Initial Public Offering. The advances were non-interest bearing and due on demand. The advances were repaid on May 15, 2019.    Promissory Note – Related Party   On December 19, 2018, the Sponsor agreed to loan the Company an aggregate of up to $300,000 to cover expenses related to the Initial Public Offering (the "Promissory Note"). The Promissory Note was non-interest bearing and payable on the completion of the Initial Public Offering. The outstanding amount of $300,000 under the Promissory Note was repaid May 15, 2019.   Related Party Loans   In addition, in order to finance transaction costs in connection with a Business Combination, the initial stockholders or their affiliates may, but are not obligated to, loan the Company funds as may be required ("Working Capital Loans"). If the Company completes a Business Combination, the Company would repay the Working Capital Loans out of the proceeds of the Trust Account released to the Company. Otherwise, the Working Capital Loans would be repaid only out of funds held outside the Trust Account. In the event that a Business Combination does not close, the Company may use a portion of proceeds held outside the Trust Account to repay the Working Capital Loans, but no proceeds held in the Trust Account would be used to repay the Working Capital Loans. Except for the foregoing, the terms of such Working Capital Loans, if any, have not been determined and no written agreements exist with respect to such loans. The Working Capital Loans would either be repaid upon consummation of a Business Combination, without interest, or, at the lender's discretion, up to $200,000 of such Working Capital Loans may be convertible into warrants of the post-Business Combination entity at a price of $0.50 per warrant. The warrants would be identical to the Private Warrants. There were no borrowings under the Working Capital Loans as of June 30, 2019.   Share Purchase Obligation   The Sponsor has entered into an agreement to purchase an aggregate of $20,000,000 of the Company's shares of common stock in a private placement that would occur concurrently with the consummation of a Business Combination. The capital from such private placement may be used as part of the consideration to the sellers in a Business Combination, and any excess capital from such private placement would be used for working capital in the post-transaction company.   Administrative Support Agreement   The Company entered into an agreement whereby, commencing on the May 9, 2019 through the earlier of the Company's consummation of a Business Combination and its liquidation, the Company will pay the Sponsor a total of $10,000 per month for office space, utilities and secretarial support. For the three and six months ended June 30, 2019, the Company incurred $20,000 in fees for these services.

NOTE 5. COMMITMENTS   Registration Rights   Pursuant to a registration rights agreement entered into on May 9, 2019, the holders of the Founder Shares, Private Warrants (including securities contained therein) and any shares that may be issued upon conversion of Working Capital Loans will be entitled to registration rights. The holders of a majority of these securities are entitled to make up to two demands that the Company register such securities. The holders of the majority of the Founder Shares can elect to exercise these registration rights at any time commencing three months prior to the date on which these shares of common stock are to be released from escrow. The holders of a majority of the Private Warrants or units issued in payment the Working Capital Loans may elect to exercise these registration rights at any time commencing on the date that the Company consummates a Business Combination. In addition, the holders have certain "piggy-back" registration rights with respect to registration statements filed subsequent to the consummation of a Business Combination. The Company will bear the expenses incurred in connection with the filing of any such registration statements.   Underwriting Agreement   The underwriters are entitled to a deferred fee of $0.35 per Unit, or $4,025,000 in the aggregate. The deferred fee will become payable to the underwriters from the amounts held in the Trust Account solely in the event that the Company completes a Business Combination, subject to the terms of the underwriting agreement.

NOTE 6. STOCKHOLDER'S EQUITY   Common Stock — On May 9, 2019, the Company filed an Amended and Restated Certificate of Incorporation such that the Company is authorized to issue 30,000,000 shares of common stock with a par value of $0.0001 per share. Holders of common stock are entitled to one vote for each share. At June 30, 2019 and December 31, 2018, there were 3,545,057 and 2,875,000 shares of common stock issued and outstanding, excluding 10,829,943 and no shares of common stock subject to possible redemption, respectively. As a result of the underwriters' election to fully exercise their over-allotment option, 375,000 Founder Shares are no longer subject to forfeiture.   Warrants — The Public Warrants will become exercisable on the later of (a) 30 days after the completion of the Company's initial Business Combination or (b) May 14, 2020. The Public Warrants will expire five years after the completion of a Business Combination or earlier upon redemption or liquidation.   The Company will not be obligated to deliver any shares of common stock pursuant to the exercise of a warrant and will have no obligation to settle such warrant exercise unless a registration statement under the Securities Act with respect to the shares of common stock underlying the warrants is then effective and a prospectus relating thereto is current, subject to the Company satisfying its obligations with respect to registration. No warrant will be exercisable and the Company will not be obligated to issue shares of common stock upon exercise of a warrant unless the common stock issuable upon such warrant exercise has been registered, qualified or deemed to be exempt under the securities laws of the state of residence of the registered holder of the warrants.   The Company has agreed that, as soon as practicable, but in no event later than thirty (30) business days after the closing of a Business Combination, the Company will use its best efforts to file with the SEC a registration statement for the registration, under the Securities Act, of the shares of common stock issuable upon exercise of the warrants. The Company will use its best efforts to cause the same to become effective and to maintain the effectiveness of such registration statement, and a current prospectus relating thereto, until the expiration of the warrants in accordance with the provisions of the warrant agreement. In addition, the Company has agreed to use its best efforts to register the shares of common stock that are issuable upon exercise of the warrants under state blue sky laws, to the extent an exemption is not available. Notwithstanding the foregoing, if a registration statement covering the shares of common stock issuable upon exercise of the warrants has not been declared effective by the 90th business day following the closing of a Business Combination and during any period when the Company shall have failed to maintain an effective registration statement, warrant holders may, until such time as there is an effective registration statement, exercise the warrants on a cashless basis pursuant to the exemption provided by Section 3(a)(9) of the Securities Act.   Once the warrants become exercisable, the Company may redeem the Public Warrants:   <table cellspacing="0" cellpadding="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse"> <tr style="vertical-align: top"> <td style="width: 0.25in; padding: 0; text-indent: 0"> </td> <td style="width: 0.25in; padding: 0; text-align: justify; text-indent: 0">●</td> <td style="padding: 0; text-align: justify; text-indent: 0">in whole and not in part;</td></tr> <tr style="vertical-align: top"> <td style="padding: 0; text-indent: 0"> </td> <td style="padding: 0; text-align: justify; text-indent: 0"> </td> <td style="padding: 0; text-align: justify; text-indent: 0"> </td></tr> <tr style="vertical-align: top"> <td style="padding: 0; text-indent: 0"> </td> <td style="padding: 0; text-align: justify; text-indent: 0">●</td> <td style="padding: 0; text-align: justify; text-indent: 0">at a price of $0.01 per warrant;</td></tr> <tr style="vertical-align: top"> <td style="padding: 0; text-indent: 0"> </td> <td style="padding: 0; text-align: justify; text-indent: 0"> </td> <td style="padding: 0; text-align: justify; text-indent: 0"> </td></tr> <tr style="vertical-align: top"> <td style="padding: 0; text-indent: 0"> </td> <td style="padding: 0; text-align: justify; text-indent: 0">●</td> <td style="padding: 0; text-align: justify; text-indent: 0">upon a minimum of 30 days' prior written notice of redemption; and</td></tr> <tr style="vertical-align: top"> <td style="padding: 0; text-indent: 0"> </td> <td style="padding: 0; text-align: justify; text-indent: 0"> </td> <td style="padding: 0; text-align: justify; text-indent: 0"> </td></tr> <tr style="vertical-align: top"> <td style="padding: 0; text-indent: 0"> </td> <td style="padding: 0; text-align: justify; text-indent: 0">●</td> <td style="padding: 0; text-align: justify; text-indent: 0">if, and only if, the last sale price of the Company's common stock equals or exceeds $16.50 per share for any 20 trading days within a 30-trading day period ending on the third trading day prior to the date on which the Company sends the notice of redemption to the warrant holders.</td></tr> </table>   The Private Warrants are identical to the Public Warrants underlying the Units sold in the Initial Public Offering, except that the Private Warrants and the common stock issuable upon the exercise of the Private Warrants will not be transferable, assignable or salable until after the completion of a Business Combination, subject to certain limited exceptions. Additionally, the Private Warrants will be exercisable on a cashless basis and be non-redeemable so long as they are held by the initial purchasers or their permitted transferees. If the Private Warrants are held by someone other than the initial purchasers or their permitted transferees, the Private Warrants will be redeemable by the Company and exercisable by such holders on the same basis as the Public Warrants.   If the Company calls the Public Warrants for redemption, management will have the option to require all holders that wish to exercise the Public Warrants to do so on a "cashless basis," as described in the warrant agreement. The exercise price and number of shares of common stock issuable upon exercise of the warrants may be adjusted in certain circumstances including in the event of a stock dividend, or recapitalization, reorganization, merger or consolidation. However, the warrants will not be adjusted for issuance of common stock at a price below its exercise price. Additionally, in no event will the Company be required to net cash settle the warrants. If the Company is unable to complete a Business Combination within the Combination Period and the Company liquidates the funds held in the Trust Account, holders of warrants will not receive any of such funds with respect to their warrants, nor will they receive any distribution from the Company's assets held outside of the Trust Account with the respect to such warrants. Accordingly, the warrants may expire worthless.

NOTE 8. SUBSEQUENT EVENTS   The Company evaluated subsequent events and transactions that occurred after the balance sheet date up to the date that the condensed financial statements were issued. Based on this review, the Company did not identify any subsequent events that would have required adjustment or disclosure in the condensed financial statements.

300000

20000 20000 10000

NOTE 7. FAIR VALUE MEASUREMENTS   The Company classifies its U. S. Treasury and equivalent securities as held-to-maturity in accordance with ASC 320 "Investments - Debt and Equity Securities." Held-to-maturity securities are those securities which the Company has the ability and intent to hold until maturity. Held-to-maturity treasury securities are recorded at amortized cost on the accompanying condensed balance sheets and adjusted for the amortization or accretion of premiums or discounts.   At June 30, 2019, assets held in the Trust Account were comprised of $8,783 in cash and $115,332,775 in U.S. Treasury Bills.   The gross holding losses and fair value of held-to-maturity securities at June 30, 2019 are as follows:   <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Held-To-Maturity</td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Amortized Cost</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Gross Holding Gain</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Fair Value</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 4pt; width: 13%">June 30, 2019</td><td style="width: 1%; padding-bottom: 4pt"> </td> <td style="width: 50%; text-align: left; padding-bottom: 4pt">U.S. Treasury Securities (Mature on 11/14/2019)</td><td style="width: 1%; padding-bottom: 4pt"> </td> <td style="width: 1%; border-bottom: Black 4pt double; text-align: left">$</td><td style="width: 9%; border-bottom: Black 4pt double; text-align: right">115,332,775</td><td style="width: 1%; padding-bottom: 4pt; text-align: left"> </td><td style="width: 1%; padding-bottom: 4pt"> </td> <td style="width: 1%; border-bottom: Black 4pt double; text-align: left">$</td><td style="width: 9%; border-bottom: Black 4pt double; text-align: right">114,349</td><td style="width: 1%; padding-bottom: 4pt; text-align: left"> </td><td style="width: 1%; padding-bottom: 4pt"> </td> <td style="width: 1%; border-bottom: Black 4pt double; text-align: left">$</td><td style="width: 9%; border-bottom: Black 4pt double; text-align: right">115,447,124</td><td style="width: 1%; padding-bottom: 4pt; text-align: left"> </td></tr> </table>   The fair value of the Company's financial assets and liabilities reflects management's estimate of amounts that the Company would have received in connection with the sale of the assets or paid in connection with the transfer of the liabilities in an orderly transaction between market participants at the measurement date. In connection with measuring the fair value of its assets and liabilities, the Company seeks to maximize the use of observable inputs (market data obtained from independent sources) and to minimize the use of unobservable inputs (internal assumptions about how market participants would price assets and liabilities). The following fair value hierarchy is used to classify assets and liabilities based on the observable inputs and unobservable inputs used in order to value the assets and liabilities:   <table cellspacing="0" cellpadding="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse"> <tr style="vertical-align: top"> <td style="width: 6%; padding: 0; text-indent: 0"> </td> <td style="width: 8%; padding: 0; text-indent: 0">Level 1:</td> <td style="width: 86%; padding: 0; text-indent: 0; text-align: justify">Quoted prices in active markets for identical assets or liabilities. An active market for an asset or liability is a market in which transactions for the asset or liability occur with sufficient frequency and volume to provide pricing information on an ongoing basis.</td></tr> <tr style="vertical-align: top"> <td style="padding: 0; text-indent: 0"> </td> <td style="padding: 0; text-indent: 0"> </td> <td style="padding: 0; text-align: justify; text-indent: 0"> </td></tr> <tr style="vertical-align: top"> <td style="padding: 0; text-indent: 0"> </td> <td style="padding: 0; text-indent: 0">Level 2:</td> <td style="padding: 0; text-indent: 0; text-align: justify">Observable inputs other than Level 1 inputs. Examples of Level 2 inputs include quoted prices in active markets for similar assets or liabilities and quoted prices for identical assets or liabilities in markets that are not active.</td></tr> <tr style="vertical-align: top"> <td style="padding: 0; text-indent: 0"> </td> <td style="padding: 0; text-indent: 0"> </td> <td style="padding: 0; text-align: justify; text-indent: 0"> </td></tr> <tr style="vertical-align: top"> <td style="padding: 0; text-indent: 0"> </td> <td style="padding: 0; text-indent: 0">Level 3:</td> <td style="padding: 0; text-indent: 0; text-align: justify">Unobservable inputs based on our assessment of the assumptions that market participants would use in pricing the asset or liability.</td></tr></table>

<table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"><tr style="vertical-align: bottom"><td style="text-align: center"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Held-To-Maturity</td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Amortized Cost</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Gross Holding Gain</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Fair Value</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 4pt; width: 13%">June 30, 2019</td><td style="width: 1%; padding-bottom: 4pt"> </td> <td style="width: 50%; text-align: left; padding-bottom: 4pt">U.S. Treasury Securities (Mature on 11/14/2019)</td><td style="width: 1%; padding-bottom: 4pt"> </td> <td style="width: 1%; border-bottom: Black 4pt double; text-align: left">$</td><td style="width: 9%; border-bottom: Black 4pt double; text-align: right">115,332,775</td><td style="width: 1%; padding-bottom: 4pt; text-align: left"> </td><td style="width: 1%; padding-bottom: 4pt"> </td> <td style="width: 1%; border-bottom: Black 4pt double; text-align: left">$</td><td style="width: 9%; border-bottom: Black 4pt double; text-align: right">114,349</td><td style="width: 1%; padding-bottom: 4pt; text-align: left"> </td><td style="width: 1%; padding-bottom: 4pt"> </td> <td style="width: 1%; border-bottom: Black 4pt double; text-align: left">$</td><td style="width: 9%; border-bottom: Black 4pt double; text-align: right">115,447,124</td><td style="width: 1%; padding-bottom: 4pt; text-align: left"> </td></tr></table> U.S. Treasury Securities (Mature on 11/14/2019)

115332775

114349

115447124

8783

1911852 375000 false

375000

25050 24600

NOTE 2. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES   Basis of presentation   The accompanying unaudited condensed financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America (“GAAP”) for interim financial information and in accordance with the instructions to Form 10-Q and Article 8 of Regulation S-X of the SEC. Certain information or footnote disclosures normally included in financial statements prepared in accordance with GAAP have been condensed or omitted, pursuant to the rules and regulations of the SEC for interim financial reporting. Accordingly, they do not include all the information and footnotes necessary for a complete presentation of financial position, results of operations, or cash flows. In the opinion of management, the accompanying unaudited condensed financial statements include all adjustments, consisting of a normal recurring nature, which are necessary for a fair presentation of the financial position, operating results and cash flows for the periods presented.   The accompanying unaudited condensed financial statements should be read in conjunction with the Company’s <a href="http://www.sec.gov/Archives/edgar/data/1764013/000161577419007495/s118185_424b4.htm">prospectus</a> for its Initial Public Offering as filed with the SEC on May 10, 2019, as well as the Company’s Current Report on <a href="http://www.sec.gov/Archives/edgar/data/1764013/000161577419007917/s118326_8k.htm">Form 8-K</a>, as filed with the SEC on May 15, 2019. The interim results for the three and six months ended June 30, 2019 are not necessarily indicative of the results to be expected for the year ended December 31, 2019 or for any future periods.   Emerging growth company   The Company is an “emerging growth company,” as defined in Section 2(a) of the Securities Act, as modified by the Jumpstart Our Business Startups Act of 2012 (the “JOBS Act”), and it may take advantage of certain exemptions from various reporting requirements that are applicable to other public companies that are not emerging growth companies including, but not limited to, not being required to comply with the independent registered public accounting firm attestation requirements of Section 404 of the Sarbanes-Oxley Act, reduced disclosure obligations regarding executive compensation in its periodic reports and proxy statements, and exemptions from the requirements of holding a nonbinding advisory vote on executive compensation and stockholder approval of any golden parachute payments not previously approved.   Further, Section 102(b)(1) of the JOBS Act exempts emerging growth companies from being required to comply with new or revised financial accounting standards until private companies (that is, those that have not had a Securities Act registration statement declared effective or do not have a class of securities registered under the Exchange Act) are required to comply with the new or revised financial accounting standards. The JOBS Act provides that a company can elect to opt out of the extended transition period and comply with the requirements that apply to non-emerging growth companies but any such election to opt out is irrevocable. The Company has elected not to opt out of such extended transition period, which means that when a standard is issued or revised and it has different application dates for public or private companies, the Company, as an emerging growth company, can adopt the new or revised standard at the time private companies adopt the new or revised standard. This may make comparison of the Company’s financial statements with another public company which is neither an emerging growth company nor an emerging growth company which has opted out of using the extended transition period difficult or impossible because of the potential differences in accounting standards used.   Use of estimates   The preparation of condensed financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the condensed financial statements and the reported amounts of revenues and expenses during the reporting period.   Making estimates requires management to exercise significant judgment. It is at least reasonably possible that the estimate of the effect of a condition, situation or set of circumstances that existed at the date of the financial statement, which management considered in formulating its estimate, could change in the near term due to one or more future confirming events. Accordingly, the actual results could differ significantly from those estimates.    Common stock subject to possible redemption   The Company accounts for its common stock subject to possible redemption in accordance with the guidance in Accounting Standards Codification (“ASC”) Topic 480 “Distinguishing Liabilities from Equity.” Common stock subject to mandatory redemption is classified as a liability instrument and is measured at fair value. Conditionally redeemable common stock (including common stock that features redemption rights that is either within the control of the holder or subject to redemption upon the occurrence of uncertain events not solely within the Company’s control) is classified as temporary equity. At all other times, common stock is classified as stockholders’ equity. The Company’s common stock features certain redemption rights that are considered to be outside of the Company’s control and subject to occurrence of uncertain future events. Accordingly, at June 30, 2019, common stock subject to possible redemption is presented as temporary equity, outside of the stockholders’ equity section of the Company’s condensed balance sheet.   Offering costs   Offering costs consist of legal, accounting, underwriting fees and other costs incurred through the balance sheet date that were directly related to the Initial Public Offering. Offering costs amounting to $6,907,415 were charged to stockholders’ equity upon the completion of the Initial Public Offering.   Income taxes   The Company follows the asset and liability method of accounting for income taxes under ASC 740, “Income Taxes.” Deferred tax assets and liabilities are recognized for the estimated future tax consequences attributable to differences between the financial statements carrying amounts of existing assets and liabilities and their respective tax bases. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in income in the period that included the enactment date. Valuation allowances are established, when necessary, to reduce deferred tax assets to the amount expected to be realized. As of June 30, 2019 and December 31, 2018, the Company had a deferred tax asset of approximately $14,000 and $0, respectively, which had a full valuation allowance recorded against it of approximately $4,000 and $30, respectively. Deferred tax assets were not deemed to be material as of June 30, 2019 and December 31, 2018.   The Company’s currently taxable income primarily consists of interest income on the Trust Account. The Company’s general and administrative costs are generally considered start-up costs and are not currently deductible. During the three and six months ended June 30, 2019, the Company recorded income tax expense of approximately $66,000 respectively, primarily related to interest income earned on the Trust Account. The Company’s effective tax rate for the three and six months ended June 30, 2019 was approximately 26.7% respectively which differs from the expected income tax rate due to the start-up costs (discussed above) which are not currently deductible.    ASC 740 prescribes a recognition threshold and a measurement attribute for the financial statement recognition and measurement of tax positions taken or expected to be taken in a tax return. For those benefits to be recognized, a tax position must be more likely than not to be sustained upon examination by taxing authorities. The Company recognizes accrued interest and penalties related to unrecognized tax benefits as income tax expense. There were no unrecognized tax benefits and no amounts accrued for interest and penalties as of June 30, 2019 and December 31, 2018. The Company is currently not aware of any issues under review that could result in significant payments, accruals or material deviation from its position. The Company is subject to income tax examinations by major taxing authorities since inception.   Net loss per share   Net income (loss) per common share is computed by dividing net income (loss) by the weighted average number of common shares outstanding for the period. The Company has not considered the effect of warrants sold in the Initial Public Offering and private placement to purchase an aggregate of 10,750,000 shares of common stock in the calculation of diluted income (loss) per share, since the exercise of the warrants are contingent upon the occurrence of future events and the inclusion of such warrants would be anti-dilutive under the treasury stock method.   The Company’s statements of operations includes a presentation of income (loss) per share for common shares subject to redemption in a manner similar to the two-class method of income per share. Net income per common share, basic and diluted for redeemable common stock is calculated by dividing the interest income earned on the Trust Account, net of applicable franchise and income taxes of approximately $92,000, by the weighted average number of shares of redeemable common stock outstanding. Net loss per common share, basic and diluted for non-redeemable common stock is calculated by dividing the net income (loss), less income attributable to redeemable common stock, by the weighted average number of non-redeemable common stock outstanding for the period. Non-redeemable common stock includes the Founder Shares as these shares do not have any redemption features and do not participate in the income earned on the Trust Account.   Concentration of credit risk   Financial instruments that potentially subject the Company to concentration of credit risk consist of a cash account in a financial institution, which, at times, may exceed the Federal Depository Insurance Coverage of $250,000. At June 30, 2019 and December 31, 2018, the Company had not experienced losses on this account and management believes the Company is not exposed to significant risks on such account.    Financial instruments   The fair value of the Company’s assets and liabilities, which qualify as financial instruments under ASC Topic 820, “Fair Value Measurements and Disclosures,” approximates the carrying amounts represented in the accompanying condensed balance sheets, primarily due to their short-term nature.   Recently issued accounting standards   Management does not believe that any recently issued, but not yet effective, accounting pronouncements, if currently adopted, would have a material effect on the Company’s condensed financial statements.

Income taxes   The Company follows the asset and liability method of accounting for income taxes under ASC 740, “Income Taxes.” Deferred tax assets and liabilities are recognized for the estimated future tax consequences attributable to differences between the financial statements carrying amounts of existing assets and liabilities and their respective tax bases. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in income in the period that included the enactment date. Valuation allowances are established, when necessary, to reduce deferred tax assets to the amount expected to be realized. As of June 30, 2019 and December 31, 2018, the Company had a deferred tax asset of approximately $14,000 and $0, respectively, which had a full valuation allowance recorded against it of approximately $4,000 and $30, respectively. Deferred tax assets were not deemed to be material as of June 30, 2019 and December 31, 2018.   The Company’s currently taxable income primarily consists of interest income on the Trust Account. The Company’s general and administrative costs are generally considered start-up costs and are not currently deductible. During the three and six months ended June 30, 2019, the Company recorded income tax expense of approximately $66,000 respectively, primarily related to interest income earned on the Trust Account. The Company’s effective tax rate for the three and six months ended June 30, 2019 was approximately 26.7% respectively which differs from the expected income tax rate due to the start-up costs (discussed above) which are not currently deductible.    ASC 740 prescribes a recognition threshold and a measurement attribute for the financial statement recognition and measurement of tax positions taken or expected to be taken in a tax return. For those benefits to be recognized, a tax position must be more likely than not to be sustained upon examination by taxing authorities. The Company recognizes accrued interest and penalties related to unrecognized tax benefits as income tax expense. There were no unrecognized tax benefits and no amounts accrued for interest and penalties as of June 30, 2019 and December 31, 2018. The Company is currently not aware of any issues under review that could result in significant payments, accruals or material deviation from its position. The Company is subject to income tax examinations by major taxing authorities since inception.

Net loss per share   Net income (loss) per common share is computed by dividing net income (loss) by the weighted average number of common shares outstanding for the period. The Company has not considered the effect of warrants sold in the Initial Public Offering and private placement to purchase an aggregate of 10,750,000 shares of common stock in the calculation of diluted income (loss) per share, since the exercise of the warrants are contingent upon the occurrence of future events and the inclusion of such warrants would be anti-dilutive under the treasury stock method.   The Company’s statements of operations includes a presentation of income (loss) per share for common shares subject to redemption in a manner similar to the two-class method of income per share. Net income per common share, basic and diluted for redeemable common stock is calculated by dividing the interest income earned on the Trust Account, net of applicable franchise and income taxes of approximately $92,000, by the weighted average number of shares of redeemable common stock outstanding. Net loss per common share, basic and diluted for non-redeemable common stock is calculated by dividing the net income (loss), less income attributable to redeemable common stock, by the weighted average number of non-redeemable common stock outstanding for the period. Non-redeemable common stock includes the Founder Shares as these shares do not have any redemption features and do not participate in the income earned on the Trust Account.

14375000 Included up to 375,000 shares subject to forfeiture if the over-allotment option was not exercised in full or in part by the underwriters (see Note 4).

EX-101.SCH 7 hsac-20190630.xsd XBRL SCHEMA FILE 00000001 - Document - Document and Entity Information link:presentationLink link:calculationLink link:definitionLink 00000002 - Statement - Condensed Balance Sheets link:presentationLink link:calculationLink link:definitionLink 00000003 - Statement - Condensed Balance Sheets (Parenthetical) link:presentationLink link:calculationLink link:definitionLink 00000004 - Statement - Condensed Statements of Operations (Unaudited) link:presentationLink link:calculationLink link:definitionLink 00000005 - Statement - Condensed Statements of Changes in Stockholders' Equity (Unaudited) link:presentationLink link:calculationLink link:definitionLink 00000006 - Statement - Condensed Statements of Changes in Stockholders' Equity (Parenthetical) (Unaudited) link:presentationLink link:calculationLink link:definitionLink 00000007 - Statement - Condensed Statement of Cash Flows (Unaudited) link:presentationLink link:calculationLink link:definitionLink 00000008 - Disclosure - Description of Organization and Business Operations link:presentationLink link:calculationLink link:definitionLink 00000009 - Disclosure - Summary of Significant Accounting Policies link:presentationLink link:calculationLink link:definitionLink 00000010 - Disclosure - Initial Public Offering link:presentationLink link:calculationLink link:definitionLink 00000011 - Disclosure - Related Party Transactions link:presentationLink link:calculationLink link:definitionLink 00000012 - Disclosure - Commitments link:presentationLink link:calculationLink link:definitionLink 00000013 - Disclosure - Stockholder's Equity link:presentationLink link:calculationLink link:definitionLink 00000014 - Disclosure - Fair Value Measurements link:presentationLink link:calculationLink link:definitionLink 00000015 - Disclosure - Subsequent Events link:presentationLink link:calculationLink link:definitionLink 00000016 - Disclosure - Summary of Significant Accounting Policies (Policies) link:presentationLink link:calculationLink link:definitionLink 00000017 - Disclosure - Fair Value Measurements (Tables) link:presentationLink link:calculationLink link:definitionLink 00000018 - Disclosure - Description of Organization and Business Operations (Details) link:presentationLink link:calculationLink link:definitionLink 00000019 - Disclosure - Summary of Significant Accounting Policies (Details) link:presentationLink link:calculationLink link:definitionLink 00000020 - Disclosure - Initial Public Offering (Details) link:presentationLink link:calculationLink link:definitionLink 00000021 - Disclosure - Related Party Transactions (Details) link:presentationLink link:calculationLink link:definitionLink 00000022 - Disclosure - Commitments (Details) link:presentationLink link:calculationLink link:definitionLink 00000023 - Disclosure - Fair Value Measurements (Details) link:presentationLink link:calculationLink link:definitionLink 00000024 - Disclosure - Fair Value Measurements (Details Textual) link:presentationLink link:calculationLink link:definitionLink 00000025 - Disclosure - Stockholder's Equity (Details) link:presentationLink link:calculationLink link:definitionLink EX-101.CAL 8 hsac-20190630_cal.xml XBRL CALCULATION FILE EX-101.DEF 9 hsac-20190630_def.xml XBRL DEFINITION FILE EX-101.LAB 10 hsac-20190630_lab.xml XBRL LABEL FILE Equity Components [Axis] Common Stock Additional Paid-in Capital Accumulated Deficit Sale of Stock [Axis] Initial Public Offering [Member] Founder Shares [Member] Private Warrants [Member] Additional Paid-In Capital Retained Earnings / Accumulated Deficit Document and Entity Information [Abstract] Entity Registrant Name Entity Central Index Key Amendment Flag Current Fiscal Year End Date Document Type Document Period End Date Document Fiscal Period Focus Document Fiscal Year Focus Entity Current Reporting Status Entity Filer Category Entity Emerging Growth Company Entity Small Business Entity Shell Company Entity Ex Transition Period Entity Common Stock, Shares Outstanding Entity File Number Entity Interactive Data Current Entity Incorporation State Country Code Statement of Financial Position [Abstract] ASSETS Current assets Cash Prepaid expenses Total Current Assets Deferred offering costs Cash and Marketable securities held in Trust Account Total Assets LIABILITIES AND STOCKHOLDER'S EQUITY Current liabilities Accrued expenses Accrued offering costs Income taxes payable Promissory note - related party Total Current Liabilities Deferred underwriting fee payable Total Liabilities Commitments and contingencies (Note 5) Common stock subject to possible redemption, 10,829,943 shares at redemption value Stockholders' Equity Common stock, $0.0001 par value; 30,000,000 shares authorized; 3,545,057 and 2,875,000 shares issued and outstanding (excluding 10,829,943 and no shares subject to possible redemption) as of June 30, 2019 and December 31, 2018, respectively (1) Additional paid-in capital Retained earnings/(Accumulated deficit) Total Stockholders' Equity Total Liabilities and Stockholders' Equity Common stock, par value Common stock, shares authorized Common stock, shares issued Common stock, shares outstanding Common stock subject to possible redemption Included up to shares subject to forfeiture Income Statement [Abstract] Operating costs Franchise taxes Loss from operations Other income: Interest income Income before provision for income taxes Provision for income taxes Net income Weighted average shares outstanding of redeemable common stock Basic and diluted net income per share, redeemable common stock Weighted average shares outstanding of non-redeemable common stock Basic and diluted net loss per share, non-redeemable common stock Statement [Table] Statement [Line Items] Additional Paid in Capital Retained Earnings/(AccumulatedDeficit) Balance Balance, shares Net loss Sale of 11,500,000 Units, net of underwriting discounts and offering costs Sale of 11,500,000 Units, net of underwriting discounts and offering costs, shares Sale of 10,000,000 Private Warrants Common stock subject to possible redemption Common stock subject to possible redemption, shares Balance Balance, shares Statement of Stockholders' Equity [Abstract] Sale of units net of underwriting discounts and offering costs Sale of private warrants Included up to shares subject to forfeiture Statement of Cash Flows [Abstract] Cash Flows from Operating Activities: Net income Adjustments to reconcile net income to net cash used in operating activities: Interest earned on cash and marketable securities held in Trust Account Changes in operating assets and liabilities: Prepaid expenses Accrued expenses Income taxes payable Net cash used in operating activities Cash Flows from Investing Activities: Investment of cash into Trust Account Net cash used in investing activities Cash Flows from Financing Activities: Proceeds from sale of Units, net of underwriting discounts paid Proceeds from sale of Private Warrants Advances from related party Repayment of advances from related party Repayment of promissory note – related party Payment of offering costs Net cash provided by financing activities Net Change in Cash Cash - Beginning of period Cash - End of period Non-Cash investing and financing activities: Initial classification of common stock subject to possible redemption Change in value of common stock subject to possible redemption Deferred underwriting fee payable Organization, Consolidation and Presentation of Financial Statements [Abstract] DESCRIPTION OF ORGANIZATION AND BUSINESS OPERATIONS Accounting Policies [Abstract] SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES Initial Public Offering [Abstract] INITIAL PUBLIC OFFERING Related Party Transactions [Abstract] RELATED PARTY TRANSACTIONS Commitments and Contingencies Disclosure [Abstract] COMMITMENTS Equity [Abstract] STOCKHOLDER'S EQUITY Fair Value Measurements [Abstract] FAIR VALUE MEASUREMENTS Subsequent Events [Abstract] SUBSEQUENT EVENTS Basis of presentation Emerging growth company Use of estimates Common stock subject to possible redemption Offering costs Income taxes Net loss per share Concentration of credit risk Financial instruments Recently issued accounting standards Fair Value Measurements [Abstract] Schedule of fair value of held-to-maturity securities Subsequent Event Type [Axis] Description of Organization and Business Operations (Textual) Consummated initial public offering of units Initial public offering price per unit Generating gross proceeds of initial public offering Consummated sale of warrants Price of per private warrant Generating gross proceeds of private placement warrants Transaction costs amount Underwriting fees Deferred underwriting fees Other offering costs Cash was held outside of trust account Public share price Net proceeds of initial public offering and sale of private warrants Business combination of public offering, description Net tangible assets of business combination Percentage of restricted redeeming shares Company's obligation to redeemed, percentage Business combination fair market value, percentage Business combination percentage of voting securities Summary of Significant Accounting Policies (Textual) Offering costs Shares of common stock that were subject to forfeiture Federal depository insurance coverage Net of applicable franchise and income taxes Initial Public Offering (Textual) Number of shares sold Purchase price Sale of stock, description Related Party Transactions (Textual) Issuance of common stock to founder, shares Aggregate price Sponsor ,description Business combination, description Aggregate purchase price Aggregate purchase price Exercise price of warrant Private placement, description Borrowings outstanding Working capital loans Purchase an aggregate shares of common stock Services fees Outstanding amount of promissory note Commitments (Textual) Underwriting agreement, description Fair Value Measurements Held-To-Maturity Amortized Cost Gross Holding Gain Fair Value Fair Value Measurements EX-101.PRE 11 hsac-20190630_pre.xml XBRL PRESENTATION FILE XML 12 R1.htm IDEA: XBRL DOCUMENT

Document and Entity Information - shares	6 Months Ended
Document and Entity Information - shares	Jun. 30, 2019	Aug. 12, 2019
Document and Entity Information [Abstract]
Entity Registrant Name	Health Sciences Acquisitions Corp
Entity Central Index Key	0001764013
Amendment Flag	false
Current Fiscal Year End Date	--12-31
Document Type	10-Q
Document Period End Date	Jun. 30, 2019
Document Fiscal Period Focus	Q2
Document Fiscal Year Focus	2019
Entity Current Reporting Status	Yes
Entity Filer Category	Non-accelerated Filer
Entity Emerging Growth Company	true
Entity Small Business	true
Entity Shell Company	true
Entity Ex Transition Period	false
Entity Common Stock, Shares Outstanding		14,375,000
Entity File Number	001-38906
Entity Interactive Data Current	Yes
Entity Incorporation State Country Code	DE

XML 13 R2.htm IDEA: XBRL DOCUMENT

Condensed Balance Sheets - USD ($)

Jun. 30, 2019

Dec. 31, 2018

Current assets

Cash

$ 1,911,852

$ 325,000

Prepaid expenses

162,093

Total Current Assets

2,073,945

Deferred offering costs

80,000

Cash and Marketable securities held in Trust Account

115,341,558

Total Assets

117,415,503

405,000

Current liabilities

Accrued expenses

24,600

448

Accrued offering costs

80,000

Income taxes payable

66,467

Promissory note - related party

300,000

Total Current Liabilities

91,067

380,448

Deferred underwriting fee payable

4,025,000

Total Liabilities

4,116,067

380,448

Commitments and contingencies (Note 5)

Common stock subject to possible redemption, 10,829,943 shares at redemption value

108,299,430

Stockholders' Equity

Common stock, $0.0001 par value; 30,000,000 shares authorized; 3,545,057 and 2,875,000 shares issued and outstanding (excluding 10,829,943 and no shares subject to possible redemption) as of June 30, 2019 and December 31, 2018, respectively (1)

^[1]

355

288

Additional paid-in capital

4,817,800

24,712

Retained earnings/(Accumulated deficit)

181,851

(448)

Total Stockholders' Equity

5,000,006

24,552

Total Liabilities and Stockholders' Equity

$ 117,415,503

$ 405,000

[1]	Included up to 375,000 shares subject to forfeiture if the over-allotment option was not exercised in full or in part by the underwriters (see Note 4).

XML 14 R3.htm IDEA: XBRL DOCUMENT

Condensed Balance Sheets (Parenthetical) - USD ($)	Jun. 30, 2019	Dec. 31, 2018
Statement of Financial Position [Abstract]
Common stock, par value	$ 0.0001	$ 0.0001
Common stock, shares authorized	30,000,000	30,000,000
Common stock, shares issued	3,545,057	2,875,000
Common stock, shares outstanding	3,545,057	2,875,000
Common stock subject to possible redemption	$ 10,829,943
Included up to shares subject to forfeiture	375,000	375,000

XML 15 R4.htm IDEA: XBRL DOCUMENT

Condensed Statements of Operations (Unaudited) - USD ($)	3 Months Ended	6 Months Ended
	Jun. 30, 2019	Jun. 30, 2019
Income Statement [Abstract]
Operating costs	$ 67,742	$ 67,742
Franchise taxes	24,600	25,050
Loss from operations	(92,342)	(92,792)
Other income:
Interest income	341,558	341,558
Income before provision for income taxes	249,216	248,766
Provision for income taxes	(66,467)	(66,467)
Net income	$ 182,749	$ 182,299
Weighted average shares outstanding of redeemable common stock	11,500,000	11,500,000
Basic and diluted net income per share, redeemable common stock	$ 0.02	$ 0.02
Weighted average shares outstanding of non-redeemable common stock	2,875,000	2,875,000
Basic and diluted net loss per share, non-redeemable common stock	$ (0.02)	$ (0.02)

XML 16 R5.htm IDEA: XBRL DOCUMENT

Condensed Statements of Changes in Stockholders' Equity (Unaudited) - USD ($)

Common Stock

Additional Paid in Capital

Retained Earnings/(AccumulatedDeficit)

Total

Balance at Dec. 31, 2018

$ 288

^[1]

$ 24,712

$ (448)

$ 24,552

Balance, shares at Dec. 31, 2018

^[1]

2,875,000

Net loss

^[1]

(450)

Balance at Mar. 31, 2019

$ 288

^[1]

24,712

(898)

24,102

Balance, shares at Mar. 31, 2019

^[1]

2,875,000

Balance at Dec. 31, 2018

$ 288

^[1]

24,712

(448)

24,552

Balance, shares at Dec. 31, 2018

^[1]

2,875,000

Net loss

182,299

Balance at Jun. 30, 2019

$ 355

^[1]

4,817,800

181,851

5,000,006

Balance, shares at Jun. 30, 2019

^[1]

3,545,057

Balance at Mar. 31, 2019

$ 288

^[1]

24,712

(898)

24,102

Balance, shares at Mar. 31, 2019

^[1]

2,875,000

Net loss

^[1]

182,749

Sale of 11,500,000 Units, net of underwriting discounts and offering costs

$ 1,150

^[1]

108,091,435

108,092,585

Sale of 11,500,000 Units, net of underwriting discounts and offering costs, shares

^[1]

11,500,000

Sale of 10,000,000 Private Warrants

^[1]

5,000,000

Common stock subject to possible redemption

$ (1,083)

^[1]

(108,298,347)

(108,299,430)

Common stock subject to possible redemption, shares

^[1]

(10,829,943)

Balance at Jun. 30, 2019

$ 355

^[1]

$ 4,817,800

$ 181,851

$ 5,000,006

Balance, shares at Jun. 30, 2019

^[1]

3,545,057

[1]	Included up to 375,000 shares subject to forfeiture if the over-allotment option was not exercised in full or in part by the underwriters (see Note 4).

- Definition

The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.

+ References + Details

XML 17 R6.htm IDEA: XBRL DOCUMENT

Condensed Statements of Changes in Stockholders' Equity (Parenthetical) (Unaudited)	6 Months Ended
	Jun. 30, 2019 shares
Statement of Stockholders' Equity [Abstract]
Sale of units net of underwriting discounts and offering costs	11,500,000
Sale of private warrants	10,000,000
Included up to shares subject to forfeiture	375,000

XML 18 R7.htm IDEA: XBRL DOCUMENT

Condensed Statement of Cash Flows (Unaudited)	6 Months Ended
Condensed Statement of Cash Flows (Unaudited)	Jun. 30, 2019 USD ($)
Cash Flows from Operating Activities:
Net income	$ 182,299
Adjustments to reconcile net income to net cash used in operating activities:
Interest earned on cash and marketable securities held in Trust Account	(341,588)
Changes in operating assets and liabilities:
Prepaid expenses	(162,093)
Accrued expenses	24,152
Income taxes payable	66,467
Net cash used in operating activities	(230,733)
Cash Flows from Investing Activities:
Investment of cash into Trust Account	(115,000,000)
Net cash used in investing activities	(115,000,000)
Cash Flows from Financing Activities:
Proceeds from sale of Units, net of underwriting discounts paid	112,700,000
Proceeds from sale of Private Warrants	5,000,000
Advances from related party	50,000
Repayment of advances from related party	(50,000)
Repayment of promissory note – related party	(300,000)
Payment of offering costs	(582,415)
Net cash provided by financing activities	116,817,585
Net Change in Cash	1,586,852
Cash - Beginning of period	325,000
Cash - End of period	1,911,852
Non-Cash investing and financing activities:
Initial classification of common stock subject to possible redemption	108,116,280
Change in value of common stock subject to possible redemption	183,150
Deferred underwriting fee payable	$ 4,025,000

XML 19 R8.htm IDEA: XBRL DOCUMENT

Description of Organization and Business Operations

6 Months Ended

Jun. 30, 2019

Organization, Consolidation and Presentation of Financial Statements [Abstract]

DESCRIPTION OF ORGANIZATION AND BUSINESS OPERATIONS

NOTE 1. DESCRIPTION OF ORGANIZATION AND BUSINESS OPERATIONS

XML 20 R9.htm IDEA: XBRL DOCUMENT

Summary of Significant Accounting Policies

6 Months Ended

Jun. 30, 2019

Accounting Policies [Abstract]

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

NOTE 2. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

Basis of presentation

Emerging growth company

Use of estimates

Common stock subject to possible redemption

Offering costs

Income taxes

Net loss per share

Concentration of credit risk

Financial instruments

Recently issued accounting standards

XML 21 R10.htm IDEA: XBRL DOCUMENT

Initial Public Offering

6 Months Ended

Jun. 30, 2019

Initial Public Offering [Abstract]

INITIAL PUBLIC OFFERING

NOTE 3. INITIAL PUBLIC OFFERING

Pursuant to the Initial Public Offering, the Company sold 11,500,000 Units at a purchase price of $10.00 per Unit, which includes the full exercise by the underwriters of their option to purchase an additional 1,500,000 Units at $10.00 per Unit. Each Unit consists of one share of common stock and one redeemable warrant ("Public Warrant"). Each Public Warrant entitles the holder to purchase one-half of one share of common stock at a price of $11.50 per whole share, subject to adjustment (see Note 6).

XML 22 R11.htm IDEA: XBRL DOCUMENT

Related Party Transactions

6 Months Ended

Jun. 30, 2019

RELATED PARTY TRANSACTIONS

NOTE 4. RELATED PARTY TRANSACTIONS

Founder Shares

In December 2018, the Sponsor purchased 2,875,000 shares (the "Founder Shares") of the Company's common stock for an aggregate price of $25,000. The Founder Shares included an aggregate of up to 375,000 shares subject to forfeiture to the extent that the underwriters' over-allotment option was not exercised in full or in part, so that the initial stockholders would own, on an as-converted basis, 20% of the Company's issued and outstanding shares after the Initial Public Offering (assuming the initial stockholders did not purchase any Public Shares in the Initial Public Offering). As a result of the underwriters' election to fully exercise their over-allotment option, 375,000 Founder Shares are no longer subject to forfeiture.

The initial stockholders have agreed not to transfer, assign or sell any of the Founder Shares (except to certain permitted transferees) until, with respect to 50% of the Founder Shares, the earlier of (i) six months after the date of the consummation of a Business Combination, or (ii) the date on which the closing price of the Company's common stock equals or exceeds $12.50 per share (as adjusted for stock splits, stock dividends, reorganizations and recapitalizations) for any 20 trading days within any 30-trading day period commencing after a Business Combination and, with respect to the remaining 50% of the Founder Shares, six months after the date of the consummation of a Business Combination, or earlier in each case, if, subsequent to a Business Combination, the Company consummates a subsequent liquidation, merger, stock exchange or other similar transaction which results in all of the Company's stockholders having the right to exchange their common stock for cash, securities or other property.

Private Placement

Advances from Related Party

Promissory Note – Related Party

On December 19, 2018, the Sponsor agreed to loan the Company an aggregate of up to $300,000 to cover expenses related to the Initial Public Offering (the "Promissory Note"). The Promissory Note was non-interest bearing and payable on the completion of the Initial Public Offering. The outstanding amount of $300,000 under the Promissory Note was repaid May 15, 2019.

Related Party Loans

In addition, in order to finance transaction costs in connection with a Business Combination, the initial stockholders or their affiliates may, but are not obligated to, loan the Company funds as may be required ("Working Capital Loans"). If the Company completes a Business Combination, the Company would repay the Working Capital Loans out of the proceeds of the Trust Account released to the Company. Otherwise, the Working Capital Loans would be repaid only out of funds held outside the Trust Account. In the event that a Business Combination does not close, the Company may use a portion of proceeds held outside the Trust Account to repay the Working Capital Loans, but no proceeds held in the Trust Account would be used to repay the Working Capital Loans. Except for the foregoing, the terms of such Working Capital Loans, if any, have not been determined and no written agreements exist with respect to such loans. The Working Capital Loans would either be repaid upon consummation of a Business Combination, without interest, or, at the lender's discretion, up to $200,000 of such Working Capital Loans may be convertible into warrants of the post-Business Combination entity at a price of $0.50 per warrant. The warrants would be identical to the Private Warrants. There were no borrowings under the Working Capital Loans as of June 30, 2019.

Share Purchase Obligation

The Sponsor has entered into an agreement to purchase an aggregate of $20,000,000 of the Company's shares of common stock in a private placement that would occur concurrently with the consummation of a Business Combination. The capital from such private placement may be used as part of the consideration to the sellers in a Business Combination, and any excess capital from such private placement would be used for working capital in the post-transaction company.

Administrative Support Agreement

The Company entered into an agreement whereby, commencing on the May 9, 2019 through the earlier of the Company's consummation of a Business Combination and its liquidation, the Company will pay the Sponsor a total of $10,000 per month for office space, utilities and secretarial support. For the three and six months ended June 30, 2019, the Company incurred $20,000 in fees for these services.

XML 23 R12.htm IDEA: XBRL DOCUMENT

Commitments

6 Months Ended

Jun. 30, 2019

Commitments and Contingencies Disclosure [Abstract]

COMMITMENTS

NOTE 5. COMMITMENTS

Registration Rights

Pursuant to a registration rights agreement entered into on May 9, 2019, the holders of the Founder Shares, Private Warrants (including securities contained therein) and any shares that may be issued upon conversion of Working Capital Loans will be entitled to registration rights. The holders of a majority of these securities are entitled to make up to two demands that the Company register such securities. The holders of the majority of the Founder Shares can elect to exercise these registration rights at any time commencing three months prior to the date on which these shares of common stock are to be released from escrow. The holders of a majority of the Private Warrants or units issued in payment the Working Capital Loans may elect to exercise these registration rights at any time commencing on the date that the Company consummates a Business Combination. In addition, the holders have certain "piggy-back" registration rights with respect to registration statements filed subsequent to the consummation of a Business Combination. The Company will bear the expenses incurred in connection with the filing of any such registration statements.

Underwriting Agreement

XML 24 R13.htm IDEA: XBRL DOCUMENT

Stockholder's Equity

6 Months Ended

Jun. 30, 2019

Equity [Abstract]

STOCKHOLDER'S EQUITY

NOTE 6. STOCKHOLDER'S EQUITY

Common Stock — On May 9, 2019, the Company filed an Amended and Restated Certificate of Incorporation such that the Company is authorized to issue 30,000,000 shares of common stock with a par value of $0.0001 per share. Holders of common stock are entitled to one vote for each share. At June 30, 2019 and December 31, 2018, there were 3,545,057 and 2,875,000 shares of common stock issued and outstanding, excluding 10,829,943 and no shares of common stock subject to possible redemption, respectively. As a result of the underwriters' election to fully exercise their over-allotment option, 375,000 Founder Shares are no longer subject to forfeiture.

Warrants — The Public Warrants will become exercisable on the later of (a) 30 days after the completion of the Company's initial Business Combination or (b) May 14, 2020. The Public Warrants will expire five years after the completion of a Business Combination or earlier upon redemption or liquidation.

Once the warrants become exercisable, the Company may redeem the Public Warrants:

	●	in whole and not in part;

	●	at a price of $0.01 per warrant;

	●	upon a minimum of 30 days' prior written notice of redemption; and

	●	if, and only if, the last sale price of the Company's common stock equals or exceeds $16.50 per share for any 20 trading days within a 30-trading day period ending on the third trading day prior to the date on which the Company sends the notice of redemption to the warrant holders.

If the Company calls the Public Warrants for redemption, management will have the option to require all holders that wish to exercise the Public Warrants to do so on a "cashless basis," as described in the warrant agreement. The exercise price and number of shares of common stock issuable upon exercise of the warrants may be adjusted in certain circumstances including in the event of a stock dividend, or recapitalization, reorganization, merger or consolidation. However, the warrants will not be adjusted for issuance of common stock at a price below its exercise price. Additionally, in no event will the Company be required to net cash settle the warrants. If the Company is unable to complete a Business Combination within the Combination Period and the Company liquidates the funds held in the Trust Account, holders of warrants will not receive any of such funds with respect to their warrants, nor will they receive any distribution from the Company's assets held outside of the Trust Account with the respect to such warrants. Accordingly, the warrants may expire worthless.

XML 25 R14.htm IDEA: XBRL DOCUMENT

Fair Value Measurements

6 Months Ended

Jun. 30, 2019

Fair Value Measurements [Abstract]

FAIR VALUE MEASUREMENTS

NOTE 7. FAIR VALUE MEASUREMENTS

The Company classifies its U. S. Treasury and equivalent securities as held-to-maturity in accordance with ASC 320 "Investments - Debt and Equity Securities." Held-to-maturity securities are those securities which the Company has the ability and intent to hold until maturity. Held-to-maturity treasury securities are recorded at amortized cost on the accompanying condensed balance sheets and adjusted for the amortization or accretion of premiums or discounts.

At June 30, 2019, assets held in the Trust Account were comprised of $8,783 in cash and $115,332,775 in U.S. Treasury Bills.

The gross holding losses and fair value of held-to-maturity securities at June 30, 2019 are as follows:

		Held-To-Maturity		Amortized Cost				Gross Holding Gain				Fair Value
June 30, 2019		U.S. Treasury Securities (Mature on 11/14/2019)		$	115,332,775			$	114,349			$	115,447,124

The fair value of the Company's financial assets and liabilities reflects management's estimate of amounts that the Company would have received in connection with the sale of the assets or paid in connection with the transfer of the liabilities in an orderly transaction between market participants at the measurement date. In connection with measuring the fair value of its assets and liabilities, the Company seeks to maximize the use of observable inputs (market data obtained from independent sources) and to minimize the use of unobservable inputs (internal assumptions about how market participants would price assets and liabilities). The following fair value hierarchy is used to classify assets and liabilities based on the observable inputs and unobservable inputs used in order to value the assets and liabilities:

	Level 1:	Quoted prices in active markets for identical assets or liabilities. An active market for an asset or liability is a market in which transactions for the asset or liability occur with sufficient frequency and volume to provide pricing information on an ongoing basis.

	Level 2:	Observable inputs other than Level 1 inputs. Examples of Level 2 inputs include quoted prices in active markets for similar assets or liabilities and quoted prices for identical assets or liabilities in markets that are not active.

	Level 3:	Unobservable inputs based on our assessment of the assumptions that market participants would use in pricing the asset or liability.

- Definition

The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.

+ References + Details

XML 26 R15.htm IDEA: XBRL DOCUMENT

Subsequent Events

6 Months Ended

Jun. 30, 2019

Subsequent Events [Abstract]

SUBSEQUENT EVENTS

NOTE 8. SUBSEQUENT EVENTS

XML 27 R16.htm IDEA: XBRL DOCUMENT

Summary of Significant Accounting Policies (Policies)	6 Months Ended
Summary of Significant Accounting Policies (Policies)	Jun. 30, 2019
Accounting Policies [Abstract]
Basis of presentation	Basis of presentation The accompanying unaudited condensed financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America ("GAAP") for interim financial information and in accordance with the instructions to Form 10-Q and Article 8 of Regulation S-X of the SEC. Certain information or footnote disclosures normally included in financial statements prepared in accordance with GAAP have been condensed or omitted, pursuant to the rules and regulations of the SEC for interim financial reporting. Accordingly, they do not include all the information and footnotes necessary for a complete presentation of financial position, results of operations, or cash flows. In the opinion of management, the accompanying unaudited condensed financial statements include all adjustments, consisting of a normal recurring nature, which are necessary for a fair presentation of the financial position, operating results and cash flows for the periods presented. The accompanying unaudited condensed financial statements should be read in conjunction with the Company's prospectus for its Initial Public Offering as filed with the SEC on May 10, 2019, as well as the Company's Current Report on Form 8-K, as filed with the SEC on May 15, 2019. The interim results for the three and six months ended June 30, 2019 are not necessarily indicative of the results to be expected for the year ended December 31, 2019 or for any future periods.
Emerging growth company	Emerging growth company The Company is an "emerging growth company," as defined in Section 2(a) of the Securities Act, as modified by the Jumpstart Our Business Startups Act of 2012 (the "JOBS Act"), and it may take advantage of certain exemptions from various reporting requirements that are applicable to other public companies that are not emerging growth companies including, but not limited to, not being required to comply with the independent registered public accounting firm attestation requirements of Section 404 of the Sarbanes-Oxley Act, reduced disclosure obligations regarding executive compensation in its periodic reports and proxy statements, and exemptions from the requirements of holding a nonbinding advisory vote on executive compensation and stockholder approval of any golden parachute payments not previously approved. Further, Section 102(b)(1) of the JOBS Act exempts emerging growth companies from being required to comply with new or revised financial accounting standards until private companies (that is, those that have not had a Securities Act registration statement declared effective or do not have a class of securities registered under the Exchange Act) are required to comply with the new or revised financial accounting standards. The JOBS Act provides that a company can elect to opt out of the extended transition period and comply with the requirements that apply to non-emerging growth companies but any such election to opt out is irrevocable. The Company has elected not to opt out of such extended transition period, which means that when a standard is issued or revised and it has different application dates for public or private companies, the Company, as an emerging growth company, can adopt the new or revised standard at the time private companies adopt the new or revised standard. This may make comparison of the Company's financial statements with another public company which is neither an emerging growth company nor an emerging growth company which has opted out of using the extended transition period difficult or impossible because of the potential differences in accounting standards used.
Use of estimates	Use of estimates The preparation of condensed financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the condensed financial statements and the reported amounts of revenues and expenses during the reporting period. Making estimates requires management to exercise significant judgment. It is at least reasonably possible that the estimate of the effect of a condition, situation or set of circumstances that existed at the date of the financial statement, which management considered in formulating its estimate, could change in the near term due to one or more future confirming events. Accordingly, the actual results could differ significantly from those estimates.
Common stock subject to possible redemption	Common stock subject to possible redemption The Company accounts for its common stock subject to possible redemption in accordance with the guidance in Accounting Standards Codification ("ASC") Topic 480 "Distinguishing Liabilities from Equity." Common stock subject to mandatory redemption is classified as a liability instrument and is measured at fair value. Conditionally redeemable common stock (including common stock that features redemption rights that is either within the control of the holder or subject to redemption upon the occurrence of uncertain events not solely within the Company's control) is classified as temporary equity. At all other times, common stock is classified as stockholders' equity. The Company's common stock features certain redemption rights that are considered to be outside of the Company's control and subject to occurrence of uncertain future events. Accordingly, at June 30, 2019, common stock subject to possible redemption is presented as temporary equity, outside of the stockholders' equity section of the Company's condensed balance sheet.
Offering costs	Offering costs Offering costs consist of legal, accounting, underwriting fees and other costs incurred through the balance sheet date that were directly related to the Initial Public Offering. Offering costs amounting to $6,907,415 were charged to stockholders' equity upon the completion of the Initial Public Offering.
Income taxes	Income taxes The Company follows the asset and liability method of accounting for income taxes under ASC 740, “Income Taxes.” Deferred tax assets and liabilities are recognized for the estimated future tax consequences attributable to differences between the financial statements carrying amounts of existing assets and liabilities and their respective tax bases. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in income in the period that included the enactment date. Valuation allowances are established, when necessary, to reduce deferred tax assets to the amount expected to be realized. As of June 30, 2019 and December 31, 2018, the Company had a deferred tax asset of approximately $14,000 and $0, respectively, which had a full valuation allowance recorded against it of approximately $4,000 and $30, respectively. Deferred tax assets were not deemed to be material as of June 30, 2019 and December 31, 2018. The Company’s currently taxable income primarily consists of interest income on the Trust Account. The Company’s general and administrative costs are generally considered start-up costs and are not currently deductible. During the three and six months ended June 30, 2019, the Company recorded income tax expense of approximately $66,000 respectively, primarily related to interest income earned on the Trust Account. The Company’s effective tax rate for the three and six months ended June 30, 2019 was approximately 26.7% respectively which differs from the expected income tax rate due to the start-up costs (discussed above) which are not currently deductible. ASC 740 prescribes a recognition threshold and a measurement attribute for the financial statement recognition and measurement of tax positions taken or expected to be taken in a tax return. For those benefits to be recognized, a tax position must be more likely than not to be sustained upon examination by taxing authorities. The Company recognizes accrued interest and penalties related to unrecognized tax benefits as income tax expense. There were no unrecognized tax benefits and no amounts accrued for interest and penalties as of June 30, 2019 and December 31, 2018. The Company is currently not aware of any issues under review that could result in significant payments, accruals or material deviation from its position. The Company is subject to income tax examinations by major taxing authorities since inception.
Net loss per share	Net loss per share Net income (loss) per common share is computed by dividing net income (loss) by the weighted average number of common shares outstanding for the period. The Company has not considered the effect of warrants sold in the Initial Public Offering and private placement to purchase an aggregate of 10,750,000 shares of common stock in the calculation of diluted income (loss) per share, since the exercise of the warrants are contingent upon the occurrence of future events and the inclusion of such warrants would be anti-dilutive under the treasury stock method. The Company’s statements of operations includes a presentation of income (loss) per share for common shares subject to redemption in a manner similar to the two-class method of income per share. Net income per common share, basic and diluted for redeemable common stock is calculated by dividing the interest income earned on the Trust Account, net of applicable franchise and income taxes of approximately $92,000, by the weighted average number of shares of redeemable common stock outstanding. Net loss per common share, basic and diluted for non-redeemable common stock is calculated by dividing the net income (loss), less income attributable to redeemable common stock, by the weighted average number of non-redeemable common stock outstanding for the period. Non-redeemable common stock includes the Founder Shares as these shares do not have any redemption features and do not participate in the income earned on the Trust Account.
Concentration of credit risk	Concentration of credit risk Financial instruments that potentially subject the Company to concentration of credit risk consist of a cash account in a financial institution, which, at times, may exceed the Federal Depository Insurance Coverage of $250,000. At June 30, 2019 and December 31, 2018, the Company had not experienced losses on this account and management believes the Company is not exposed to significant risks on such account.
Financial instruments	Financial instruments The fair value of the Company's assets and liabilities, which qualify as financial instruments under ASC Topic 820, "Fair Value Measurements and Disclosures," approximates the carrying amounts represented in the accompanying condensed balance sheets, primarily due to their short-term nature.
Recently issued accounting standards	Recently issued accounting standards Management does not believe that any recently issued, but not yet effective, accounting pronouncements, if currently adopted, would have a material effect on the Company's condensed financial statements.

XML 28 R17.htm IDEA: XBRL DOCUMENT

Fair Value Measurements (Tables)

6 Months Ended

Jun. 30, 2019

Fair Value Measurements Tables Abstract

Schedule of fair value of held-to-maturity securities

		Held-To-Maturity		Amortized Cost				Gross Holding Gain				Fair Value
June 30, 2019		U.S. Treasury Securities (Mature on 11/14/2019)		$	115,332,775			$	114,349			$	115,447,124

XML 29 R18.htm IDEA: XBRL DOCUMENT

Description of Organization and Business Operations (Details) - USD ($)		6 Months Ended
	May 14, 2019	Jun. 30, 2019
Description of Organization and Business Operations (Textual)
Initial public offering price per unit	$ 10.00
Generating gross proceeds of initial public offering		$ 6,907,415
Generating gross proceeds of private placement warrants		5,000,000
Transaction costs amount	$ 6,907,415
Underwriting fees	2,300,000
Deferred underwriting fees	4,025,000
Other offering costs	582,415
Cash was held outside of trust account		$ 1,911,852
Public share price		$ 10.00
Net proceeds of initial public offering and sale of private warrants	$ 115,000,000
Business combination of public offering, description		The Company will have until May 14, 2021 to complete a Business Combination (the “Combination Period”). If the Company is unable to complete a Business Combination within the Combination Period, the Company will (i) cease all operations except for the purpose of winding up, (ii) as promptly as reasonably possible but not more than ten business days thereafter, redeem 100% of the outstanding Public Shares for a pro rata portion of the funds held in the Trust Account, which redemption will completely extinguish public stockholders’ rights as stockholders (including the right to receive further liquidating distributions, if any), subject to applicable law, and (iii) as promptly as reasonably possible following such redemption, subject to the approval of the Company’s remaining stockholders and the Company’s board of directors, dissolve and liquidate, subject in each case to the Company’s obligations under Delaware law to provide for claims of creditors and the requirements of other applicable law.
Net tangible assets of business combination		$ 5,000,001
Percentage of restricted redeeming shares		20.00%
Company's obligation to redeemed, percentage		100.00%
Business combination fair market value, percentage		80.00%
Business combination percentage of voting securities		50.00%
Initial Public Offering [Member]
Description of Organization and Business Operations (Textual)
Consummated initial public offering of units	11,500,000
Initial public offering price per unit	$ 10.00
Generating gross proceeds of initial public offering	$ 115,000,000
Consummated sale of warrants		11,500,000
Price of per private warrant		$ 10.00
Private Warrants [Member]
Description of Organization and Business Operations (Textual)
Consummated initial public offering of units		10,000,000
Consummated sale of warrants	10,000,000
Price of per private warrant	$ 0.50
Generating gross proceeds of private placement warrants	$ 5,000,000

XML 30 R19.htm IDEA: XBRL DOCUMENT

Summary of Significant Accounting Policies (Details)	6 Months Ended
Summary of Significant Accounting Policies (Details)	Jun. 30, 2019 USD ($) shares
Summary of Significant Accounting Policies (Textual)
Offering costs	$ 6,907,415
Shares of common stock that were subject to forfeiture \| shares	10,750,000
Federal depository insurance coverage	$ 250,000
Net of applicable franchise and income taxes	$ 92,000

XML 31 R20.htm IDEA: XBRL DOCUMENT

Initial Public Offering (Details) - Initial Public Offering [Member]	6 Months Ended
	Jun. 30, 2019 $ / shares shares
Initial Public Offering (Textual)
Number of shares sold \| shares	11,500,000
Purchase price \| $ / shares	$ 10.00
Sale of stock, description	Pursuant to the Initial Public Offering, the Company sold 11,500,000 Units at a purchase price of $10.00 per Unit, which includes the full exercise by the underwriters of their option to purchase an additional 1,500,000 Units at $10.00 per Unit. Each Unit consists of one share of common stock and one redeemable warrant (“Public Warrant”). Each Public Warrant entitles the holder to purchase one-half of one share of common stock at a price of $11.50 per whole share, subject to adjustment (see Note 6)

XML 32 R21.htm IDEA: XBRL DOCUMENT

Related Party Transactions (Details) - USD ($)			1 Months Ended		3 Months Ended	6 Months Ended	12 Months Ended
Related Party Transactions (Details) - USD ($)	May 14, 2019	May 09, 2019	May 31, 2019	Dec. 19, 2018	Jun. 30, 2019	Jun. 30, 2019	Dec. 31, 2018
Related Party Transactions (Textual)
Aggregate purchase price						$ 5,000,000
Exercise price of warrant					$ 0.50	$ 0.50
Advances from related party						$ 50,000
Working capital loans					$ 200,000	200,000
Purchase an aggregate shares of common stock					20,000,000	20,000,000
Services fees		$ 10,000			20,000	20,000
Outstanding amount of promissory note					$ 300,000	$ 300,000
Founder Shares [Member]
Related Party Transactions (Textual)
Issuance of common stock to founder, shares							2,875,000
Aggregate price							$ 25,000
Sponsor ,description							The Founder Shares included an aggregate of up to 375,000 shares subject to forfeiture to the extent that the underwriters’ over-allotment option was not exercised in full or in part, so that the initial stockholders would own, on an as-converted basis, 20% of the Company’s issued and outstanding shares after the Initial Public Offering (assuming the initial stockholders did not purchase any Public Shares in the Initial Public Offering). As a result of the underwriters’ election to fully exercise their over-allotment option, 375,000 Founder Shares are no longer subject to forfeiture.
Business combination, description							The initial stockholders have agreed not to transfer, assign or sell any of the Founder Shares (except to certain permitted transferees) until, with respect to 50% of the Founder Shares, the earlier of (i) six months after the date of the consummation of a Business Combination, or (ii) the date on which the closing price of the Company’s common stock equals or exceeds $12.50 per share (as adjusted for stock splits, stock dividends, reorganizations and recapitalizations) for any 20 trading days within any 30-trading day period commencing after a Business Combination and, with respect to the remaining 50% of the Founder Shares, six months after the date of the consummation of a Business Combination, or earlier in each case
Private Warrants [Member]
Related Party Transactions (Textual)
Issuance of common stock to founder, shares						10,000,000
Aggregate purchase price	$ 5,000,000
Aggregate purchase price						$ 5,000,000
Exercise price of warrant					$ 0.50	$ 0.50
Private placement, description						Each Private Warrant is exercisable to purchase one-half of one share of common stock at a price of $11.50 per whole share.
Initial Public Offering [Member]
Related Party Transactions (Textual)
Issuance of common stock to founder, shares	11,500,000
Sponsor ,description						Pursuant to the Initial Public Offering, the Company sold 11,500,000 Units at a purchase price of $10.00 per Unit, which includes the full exercise by the underwriters of their option to purchase an additional 1,500,000 Units at $10.00 per Unit. Each Unit consists of one share of common stock and one redeemable warrant (“Public Warrant”). Each Public Warrant entitles the holder to purchase one-half of one share of common stock at a price of $11.50 per whole share, subject to adjustment (see Note 6)
Advances from related party			$ 50,000	$ 300,000
Borrowings outstanding					$ 300,000	$ 300,000

XML 33 R22.htm IDEA: XBRL DOCUMENT

Commitments (Details)	6 Months Ended
Commitments (Details)	Jun. 30, 2019
Commitments (Textual)
Underwriting agreement, description	The underwriters are entitled to a deferred fee of $0.35 per Unit, or $4,025,000 in the aggregate. The deferred fee will become payable to the underwriters from the amounts held in the Trust Account solely in the event that the Company completes a Business Combination, subject to the terms of the underwriting agreement.

XML 34 R23.htm IDEA: XBRL DOCUMENT

Fair Value Measurements (Details)	6 Months Ended
Fair Value Measurements (Details)	Jun. 30, 2019 USD ($)
Fair Value Measurements
Held-To-Maturity	U.S. Treasury Securities (Mature on 11/14/2019)
Amortized Cost	$ 115,332,775
Gross Holding Gain	114,349
Fair Value	$ 115,447,124

XML 35 R24.htm IDEA: XBRL DOCUMENT

Fair Value Measurements (Details Textual)	Jun. 30, 2019 USD ($)
Fair Value Measurements (Textual)
Cash	$ 8,783
U.S. Treasury Bills	$ 115,447,124

XML 36 R25.htm IDEA: XBRL DOCUMENT

Stockholder's Equity (Details) - USD ($)		6 Months Ended
Stockholder's Equity (Details) - USD ($)	May 09, 2019	Jun. 30, 2019	Dec. 31, 2018
Common stock, par value	$ 0.0001	$ 0.0001	$ 0.0001
Common stock, authorized	30,000,000	30,000,000	30,000,000
Common stock shares, issued		3,545,057	2,875,000
Common stock shares, outstanding		3,545,057	2,875,000
Description of public warrants	The Public Warrants will become exercisable on the later of (a) 30 days after the completion of the Company’s initial Business Combination or (b) May 14, 2020. The Public Warrants will expire five years after the completion of a Business Combination or earlier upon redemption or liquidation.	Once the warrants become exercisable, the Company may redeem the Public Warrants: ● in whole and not in part; ● at a price of $0.01 per warrant; ● upon a minimum of 30 days’ prior written notice of redemption; and ● if, and only if, the last sale price of the Company’s common stock equals or exceeds $16.50 per share for any 20 trading days within a 30-trading day period ending on the third trading day prior to the date on which the Company sends the notice of redemption to the warrant holders.
Aggregate shares subject to forfeiture		10,750,000
Common stock subject to possible redemption		$ 10,829,943
Founder shares		375,000

EXCEL 37 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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end XML 38 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 39 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 40 FilingSummary.xml IDEA: XBRL DOCUMENT 3.19.2 html 37 220 1 true 6 0 false 4 false false R1.htm 00000001 - Document - Document and Entity Information Sheet http://hsac.com/role/DocumentAndEntityInformation Document and Entity Information Cover 1 false false R2.htm 00000002 - Statement - Condensed Balance Sheets Sheet http://hsac.com/role/BalanceSheets Condensed Balance Sheets Statements 2 false false R3.htm 00000003 - Statement - Condensed Balance Sheets (Parenthetical) Sheet http://hsac.com/role/BalanceSheetsParenthetical Condensed Balance Sheets (Parenthetical) Statements 3 false false R4.htm 00000004 - Statement - Condensed Statements of Operations (Unaudited) Sheet http://hsac.com/role/StatementsOfOperations Condensed Statements of Operations (Unaudited) Statements 4 false false R5.htm 00000005 - Statement - Condensed Statements of Changes in Stockholders' Equity (Unaudited) Sheet http://hsac.com/role/StatementOfChangesInStockholdersEquity Condensed Statements of Changes in Stockholders' Equity (Unaudited) Statements 5 false false R6.htm 00000006 - Statement - Condensed Statements of Changes in Stockholders' Equity (Parenthetical) (Unaudited) Sheet http://hsac.com/role/StatementsOfChangesInStockholdersEquityParenthetical Condensed Statements of Changes in Stockholders' Equity (Parenthetical) (Unaudited) Statements 6 false false R7.htm 00000007 - Statement - Condensed Statement of Cash Flows (Unaudited) Sheet http://hsac.com/role/StatementOfCashFlows Condensed Statement of Cash Flows (Unaudited) Statements 7 false false R8.htm 00000008 - Disclosure - Description of Organization and Business Operations Sheet http://hsac.com/role/DescriptionOfOrganizationAndBusinessOperations Description of Organization and Business Operations Notes 8 false false R9.htm 00000009 - Disclosure - Summary of Significant Accounting Policies Sheet http://hsac.com/role/SummaryOfSignificantAccountingPolicies Summary of Significant Accounting Policies Notes 9 false false R10.htm 00000010 - Disclosure - Initial Public Offering Sheet http://hsac.com/role/InitialPublicOffering Initial Public Offering Notes 10 false false R11.htm 00000011 - Disclosure - Related Party Transactions Sheet http://hsac.com/role/RelatedPartyTransactions Related Party Transactions Notes 11 false false R12.htm 00000012 - Disclosure - Commitments Sheet http://hsac.com/role/Commitments Commitments Notes 12 false false R13.htm 00000013 - Disclosure - Stockholder's Equity Sheet http://hsac.com/role/StockholdersEquity Stockholder's Equity Notes 13 false false R14.htm 00000014 - Disclosure - Fair Value Measurements Sheet http://hsac.com/role/FairValueMeasurements Fair Value Measurements Notes 14 false false R15.htm 00000015 - Disclosure - Subsequent Events Sheet http://hsac.com/role/SubsequentEvents Subsequent Events Notes 15 false false R16.htm 00000016 - Disclosure - Summary of Significant Accounting Policies (Policies) Sheet http://hsac.com/role/SummaryOfSignificantAccountingPoliciesPolicies Summary of Significant Accounting Policies (Policies) Policies http://hsac.com/role/SummaryOfSignificantAccountingPolicies 16 false false R17.htm 00000017 - Disclosure - Fair Value Measurements (Tables) Sheet http://hsac.com/role/FairValueMeasurementsTables Fair Value Measurements (Tables) Tables http://hsac.com/role/FairValueMeasurements 17 false false R18.htm 00000018 - Disclosure - Description of Organization and Business Operations (Details) Sheet http://hsac.com/role/DescriptionOfOrganizationAndBusinessOperationsDetails Description of Organization and Business Operations (Details) Details http://hsac.com/role/DescriptionOfOrganizationAndBusinessOperations 18 false false R19.htm 00000019 - Disclosure - Summary of Significant Accounting Policies (Details) Sheet http://hsac.com/role/SummaryOfSignificantAccountingPoliciesDetails Summary of Significant Accounting Policies (Details) Details http://hsac.com/role/SummaryOfSignificantAccountingPoliciesPolicies 19 false false R20.htm 00000020 - Disclosure - Initial Public Offering (Details) Sheet http://hsac.com/role/InitialPublicOfferingDetails Initial Public Offering (Details) Details http://hsac.com/role/InitialPublicOffering 20 false false R21.htm 00000021 - Disclosure - Related Party Transactions (Details) Sheet http://hsac.com/role/RelatedPartyTransactionsDetails Related Party Transactions (Details) Details http://hsac.com/role/RelatedPartyTransactions 21 false false R22.htm 00000022 - Disclosure - Commitments (Details) Sheet http://hsac.com/role/CommitmentsDetails Commitments (Details) Details http://hsac.com/role/Commitments 22 false false R23.htm 00000023 - Disclosure - Fair Value Measurements (Details) Sheet http://hsac.com/role/FairValueMeasurementsDetails Fair Value Measurements (Details) Details http://hsac.com/role/FairValueMeasurementsTables 23 false false R24.htm 00000024 - Disclosure - Fair Value Measurements (Details Textual) Sheet http://hsac.com/role/FairValueMeasurementsDetailsTextual Fair Value Measurements (Details Textual) Details http://hsac.com/role/FairValueMeasurementsTables 24 false false R25.htm 00000025 - Disclosure - Stockholder's Equity (Details) Sheet http://hsac.com/role/StockholdersEquityDetails Stockholder's Equity (Details) Details http://hsac.com/role/StockholdersEquity 25 false false All Reports Book All Reports hsac-20190630.xml hsac-20190630.xsd hsac-20190630_cal.xml hsac-20190630_def.xml hsac-20190630_lab.xml hsac-20190630_pre.xml http://fasb.org/us-gaap/2019-01-31 http://xbrl.sec.gov/dei/2019-01-31 true true ZIP 42 0001213900-19-015337-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001213900-19-015337-xbrl.zip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